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PREFACE 
 
 
Macromolecular recognition is based on the requirement of dual geometric and chemical 
complementarity, eventually leading to the formation of a thermodynamically stable and specific 
complex between interacting molecules. These aspects are key elements for understanding the function 
of biological systems: enzymes that bind substrates and effectors, proteins that mediate signal 
transduction via networks of alternative or specific protein-protein pair, and nucleic acids that, via the 
binding of transcription factors, repressors, co-activators, regulate protein expression. In particular, the 
site-specific associations between DNA and proteins regulate most biological events, with key 
involvement in transcription, replication and recombination. In order to deeply understand the 
chemical and physical mechanisms by which the cellular components exploit their functions, a 
prerequisite is a description of their structure at atomic level. The best technique currently available for 
visualizing the structures of macromolecules at atomic scale is X-ray diffraction analysis of single 
crystals. X-ray crystallography has transformed our understanding of biological processes. For example 
it provided the first clues to the structure of the DNA double helix 50 years ago, giving profound 
insights into how DNA is replicated. Since the pioneering work of Perutz and Kendrew on the 
structure of haemoglobin and myoglobin in the late 1950s, about 60000 protein structures have been 
solved to date by X-ray crystallography. Nowadays, crystallographers and structural biologists attention 
has moved on macromolecular complexes, which control the complex signaling and molecular 
recognition processes that occur in virology, cell signaling, DNA hybridization, immunology. Indeed, 
protein-protein or protein-nucleic acids cross-talk is in many cases even more important than the 
structure of an individual molecule. 
A field where the detailed knowledge of macromolecular structures and interactions plays a pivotal role 
is drug discovery and development. The process of drug discovery involves the identification of target 
molecules (usually but not always proteins), which serve as points of attack for future medicines, the 
design and synthesis of potential lead compounds, and further characterization, screening, and assays 
for therapeutic efficacy and toxicity. Target structures do not lead directly to a drug, but the 
information of potential binding sites and substrate geometries enable a focused approach to screening 
for potential therapeutic agents. On the other hand, structures of targets in complexes with potential 
drugs may be much more useful: they suggest synthetic variation strategies, depending on optimization 
needs. For examples potency can be increased by optimizing interactions, pharmacokinetic properties 
may be improved with targeted variation of moieties not essential for binding, selectivity may be 
enhanced (or decreased) by comparing binding modes in related targets and new binding modes may be 
discovered by targeted variation of essential binding moieties. The structural information obtained 
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(where does the molecule bind; what are the ligand/protein/solvent interactions; how does the 
protein/ligand structure change upon binding) can be invaluable in the generation of novel molecules 
or in the re-design of existing molecules whose drug properties are not optimal. Thus crystallography 
has became a standard technique used by many pharmaceutical and biotechnology companies. 
However, a deeper characterization and knowledge of macromolecules dynamics, protein-protein and 
protein-nucleic acid interactions is reached when crystallography is combined with computational and 
biophysical studies, including different spectroscopic techniques.  
The present study focuses on the structural analysis of two different kind of proteins that interacts with 
nucleic acids and their ligands. The first part concerns the structural characterization of complexes 
between human α-thrombin, a protein of physiological and pathological relevance, and two 
oligonucleotidic aptamers, which adopt a quadruplex fold. This knowledge opens the door to the 
development of novel aptamers with improved antithrombotic activity, preserved stability and 
increased binding efficacy and represent a further affirmation of the crucial role of macromolecular 
crystallography for drug development.  
The second part of the thesis is subdivided into more issues. It globally deals with the study of a 
protein family, whose cellular target is RNA: the ribonucleases or RNases. This is a class of enzymes 
whose functions are much wider and fall outside the limits of simple destruction of RNA molecules. A 
particular attention is devoted to ribonucleases that, thanks to their structural features (domain 
swapping), can exert an antitumor activity. The results obtained through a combination of 
crystallographic and docking analyses allowed to identify the structural determinants of antitumor 
dimeric RNases and have been successfully utilized to convert non-cytotoxic RNase A in a dimeric 
cytotoxic mutant. These results are very useful to further improve biological properties of these 
macromolecules that can be used as a new generation of antitumor agents. 
Another topic of the thesis is the characterization of the whole ribonuclease system in zebrafish 
organism. This is an ideal vertebrate model system for phylogenetic and evolutionary analyses and for 
biomedical studies. In particular, zebrafish is considered a new powerful tool in research and drug 
discovery that will accelerate screening processes and the finding of new lifesaving drugs for humans. 
Although assay development to model human diseases in zebrafish is still in its infancy, a variety of 
diseases, among which cancer, have been successfully modelled in zebrafish. Structural determination 
by crystallography and homology modelling of these ribonucleases, endowed with angiogenic activity, 
allowed to understand the molecular bases of their different properties. Furthermore it represents a 
good starting point to study evolution of a protein scaffold from ancestral organisms to contemporary 
mammalians. 
Finally this study has regarded chimeric molecules, with specific cell-type cytotoxicity, containing 
Preface 
 
5 
 
RNase moieties. A computational approach was used to identify the epitope recognized by a powerful 
antitumor construct, immuno-RNase. This fully human fusion protein is highly selective towards tumor 
cell that overexpress the receptor ErbB2, and does not present immunogenicity nor cardiotoxicity as 
side effects, whereas approved antitumor antibodies do. Since immuno-RNase properties depend on 
the ErbB2 region that it binds, a detailed knowledge of interactions between immuno-RNase and its 
epitope is useful to implement immuno-RNase pharmacological properties, and also to design specific 
antidotes to control its effect. The study has been successful: a small ErbB2 region (14 aminoacid 
residues) bound by immuno-RNase was identified and the results obtained by our computational 
approach were also validated by experimental data. Remarkably immuno-RNase binds a different 
epitope with respect to immunoagents approved for cancer therapy. This finding on one hand could 
justify immuno-RNase lack of cardiotoxicity, on the other hand suggests that this protein could be used 
in combination with other drugs to obtain more efficient antitumoral therapies. 
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NUCLEIC ACIDS-PROTEINS INTERACTIONS: THE 
THROMBIN-APTAMERS CASE 
 
 
INTRODUCTION 
 
First discovered in 1869 DNA continues to amaze and intrigue the researchers devoted to its study. 
The Watson and Crick model for B-form duplex DNA dramatically improved the mechanistic 
understanding of the replication and flow of genetic information, termed “the central dogma of 
molecular biology” by Francis Crick in 1958. Since then, the B-form has usually been regarded as the 
biologically relevant structure of DNA. However, in the context of nucleosome core particles and other 
nucleoprotein complexes, DNA can adopt a wide variety of conformations, including highly distorted 
A-, B-, Z-form double helices [1]. In addition to various duplex structures, single stranded DNAs can 
fold into a wide variety of hairpin, triplex, G-quadruplex, and i-motif structures containing non-
canonical base pairs [2]. Single stranded DNA can exhibit structural diversity comparable, in some 
ways, to that of RNA. Polypurine–polypyrimidine tracts and other repetitive sequences can form non-
duplex and/or higher-order chromatin structures, possibly related to many different biological 
activities. One family of structures originating from guanine-rich tracts is referred to as G-quadruplex 
(or G-tetraplex)[3]. 
G-quadruplex  
Since from the fifties it is known that guanine-rich oligonucleotidic sequences can dispose in a 
quadruple helix structure, named G-quadruplex. The main component of the G-quadruplex is the G-
tetrad or G-quartet, a planar arrangement of four guanine bases associated through a cyclic array of 
Hoogsteen-like hydrogen bonds, in which each guanine base both accepts and donates two hydrogen 
bonds [4] (Figure 1). A quadruplex is composed of at least two stacked G-quartets, which can be 
connected by residues not involved in the quartet itself that define the loops [5].  
 
Figure 1 Top view of a G-quartet and its arrangement in a G-quadruplex 
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G-quadruplex can be formed by one, two or four strands and are named uni-, bi-, ore tetra-molecular, 
respectively. Furthermore they are differentiated for several structural features:  
 the orientation of the strands, which could be parallel or antiparallel, where the last term is used 
for a quadruplex with at least one strand opposite to the other ones,  
 the conformation of guanines glycosidic bonds angles,  
 the size of grooves spanning contiguous backbones,  
 the conformation of connecting loops.  
In particular three types of grooves exist, narrow, wide and medium, depending on the arrangement of 
glycosidic bonds angles of hydrogen bonded guanines. Narrow and wide grooves are the result of 
hydrogen bonded bases with different glycosidic bond angles, whereas contiguous bases with the same 
conformation form a medium groove [6]. Concerning the loop conformation, three types of loops are 
observed in quadruplexes: lateral, or edgewise, diagonal and propeller. 
The most simple quadruplex structure is the tetra-molecular one. It is composed by four strands, 
typically with the same sequence, which are parallel to each other. There is no connecting loop and all 
guanines have anti glycosidic bonds angles, resulting in grooves with the same width. The topologies 
allowed for bi-molecular and uni-molecular quadruplexes are more complex and variegate. In principle 
each arrangement of the strands is possible, parallel or antiparallel. Furthermore antiparallel 
quadruplexes are formed by guanines with both anti and syn glycosidic torsion angles, thus different 
types of grooves are observed between contiguous backbones. A great variability of structures derives 
from loop orientations and loops with different conformations can be present in a single quadruplex [7, 
8] (Figure 2).  
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Figure 2 Overview of different G-quadruplex topologies 
 
Furthermore no severe rule establishes a unique quadruplex fold for a given oligonucleotidic sequence, 
and examples of oligonucleotides that fold in different structures exist. In particular, it has been 
observed that a crucial role in determining three-dimensional structure is played by metal ions or 
molecular crowding.  
Stacked quartets line with their O6 atoms a central cavity with a strong negative electrostatic potential, 
where cations are well accommodated. In particular the coordination of potassium [9], sodium [10] and 
strontium [11] provides thermodynamic stability to the G-quadruplex structure. It has been proved that 
G-quadruplexes are stabilized by the alkaline series in the following order: 
K+>>Na+>Rb+>Cs+>>Li+, and by the alkaline earth series in the order: Sr2+>>Ba2+>Ca2+>Mg2+, 
indicating that the atomic radii of potassium and strontium fit best in the coordination site between 
adjacent G-tetrads [12, 13]. Moreover the binding of heavy metals, such as tallium [14], or of positive 
molecular groups, such as ammonium [15], has been also observed. The location of the cation with 
respect to the quartet plane strongly depends on the metal. Potassium ions are always found 
sandwiched between stacked tetrads, almost equidistant from the eight oxygen atoms [16], whereas a 
variety of coordination geometries is possible for the smaller sodium ion. Indeed, sodium ions have 
been observed on the quartet plane (coordination number four), very close to the plane (coordination 
number five, the fifth ligand being water or another metal ion) and even between the two tetrads with 
coordination number eight [17-19]. In some cases metal ion binding is determinant for the quadruplex 
conformation, and there are several well-established examples where the change from Na+ to K+ 
induces a profound structural alteration in the quadruplex fold [20-22]. 
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G-quadruplex biological roles 
The first direct evidence for the presence of G-quadruplex DNA structures in vivo came from studies 
using G-quadruplex DNA-specific antibodies to detect intermolecular structures at ciliate telomeres, 
where their formation and dissolution are cell cycle regulated [23-25]. In vertebrates, the telomeres that 
cap chromosome ends are composed of tandem repeats of the sequence d(TTAGGG)n, with a 39 
single stranded extension (G-overhang) associated with six protein factors (TRF1, TRF2, RAP1, TIN2, 
TPP1 and POT1) that form a protecting complex (shelterin) essential for genome stability [26]. 
Telomeres protect the ends of chromosomes from recombination, fusion, or being recognized as 
damaged DNA [27, 28] and need to be maintained above a critical length. Furthermore they are 
involved in the natural process of cellular senescence: at each cellular replication telomere shortening 
occurs, thus defining life of healthy cell [29]. Cellular mechanisms that counteract this loss confer 
indefinite proliferation potential, characteristic of cancerous cells [30]. The finding that telomeric 
DNAs can associate to form quadruplex structures in physiological ionic conditions is particularly 
intriguing because quadruplex structures are not recognized by telomerase. The high activity of 
telomerase in the majority of tumors combined with its absence in most adult normal tissues has 
generated considerable interest in targeting the enzyme and associated telomeres in a cancer therapeutic 
context [31-34]. In particular it has been suggested that stabilization of quadruplexes in telomeric ends 
of cancerous cell can inhibit telomerase activity and induce cellular death [35, 36].  
Furthermore quadruplex-forming guanine-rich sequences are also found in a number of cancer-related 
genes, such as c-myc [37-40], c-kit [41, 42], HIF-1α [43], VEGF [44], BCL-2 [45, 46], KRAS [47], Rb 
[48, 49] and RET protooncogene [50]. For example, it has been shown that G-quadruplexes are 
involved in transcriptional control of the c-myc oncogene [38], whose overexpression is associated with 
a variety of human malignancies, including breast, colon, cervix, small-cell lung carcinomas, 
osteosarcomas, glioblastomas, and myeloid leukemias [51-54]. Thus G-quadruplex interacting agents 
with specificity for binding to silencer element can be good anticancer agents. 
Aptamers 
Aptamers are short DNA- [55] or RNA- [56]based oligonucleotides selected from large combinatorial 
pools of sequences for their capacity to efficiently recognize targets . More important, the structure and 
conformation of aptamers can be rationally designed and tailor-made to be selectively responsive to 
various kinds of targets, including small molecules [57], biological macromolecules [58-60] and even 
cells [61, 62]. Like antibodies, aptamers exhibit high specificity and affinity for target binding. As a 
result, they may display effective interference in biological processes, which renders them not only 
valuable diagnostic tools, but also promising therapeutic agents [63]. Aptamers display a large number 
of structural arrangements, which accounts for their binding efficiency and selectivity for unrelated 
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targets. The G-quadruplex architecture is adopted by several of them, the most popular of which shows 
inhibitory properties against α-thrombin, a pharmacologically relevant protein. G-quadruplex 
conformational plasticity consents fine tuning of target recognition as obtained by aptamer selection 
[63].  
As therapeutic agents, aptamers may have some advantages over monoclonal antibodies and other 
oligonucleotide-based approaches. Unlike monoclonal antibodies, they are non-immunogenic and 
present higher heat stability. Thanks to their high affinity and specificity, it should be allowed a 
therapeutic dosing at submicromolar levels, reducing potential non-specific effects. Moreover antidotes 
can be designed to control their pharmacologic activity [64]. G-rich aptamers that adopt a G-
quadruplex structure have also the additional benefit of an enhanced cellular uptake and a certain 
resistance to serum nucleases, when compared to unstructured nucleotide sequences used in 
therapeutic approaches [65]. This latter finding is particularly significant: indeed, with the aim to obtain 
more resistant non-quadruplex aptamers, modified oligonucleotides are used. They present several 
drawbacks, including an increased toxicity and reduced specificity. On the contrary the resistant G-
quadruplex arrangement allows the use of unmodified or minimally modified oligonucleotides [65].  
Tests performed with some quadruplex aptamers have reported antiproliferative activity correlated with 
protein-binding properties [66], although specific targets have been identified for only few of them, 
such as nucleolin [67, 68] and interferon-γ [69-71]. However the most known quadruplex aptamer is the 
DNA 15-mer with anti-thrombotic activity. 
Thrombin 
α-thrombin is a trypsin-like serine protease that plays a key role in the coagulation cascade [72]. The 
coagulation is a complex process by which blood forms clots upon the damage of a blood vessel wall. 
In mammals this process involves both a cellular component, the platelet, and a protein component, 
which includes several coagulation factors. Immediately upon the injury, platelets start to aggregate: this 
process is known as primary haemostasis. Simultaneously the secondary haemostasis occurs: the 
coagulation factors circulating in the plasma as inactive zymogens trigger a complex succession of 
reactions that results in the final production of fibrin strands, which strengthen the platelet plug [73].  
The most important constituent of the coagulation cascade is α-thrombin, since it is the only enzyme 
capable of catalyzing the cleavage of soluble fibrinogen to produce insoluble fibrin clot. It is produced 
by the enzymatic cleavage of two sites on the zymogen prothrombin, or coagulation factor II, by the 
activated coagulation factor X. Apart from the processing of fibrinogen, α-thrombin also activates 
blood coagulation factors V and VIII, amplifying the coagulation cascade, because their activation 
results in a huge amplification of thrombin generation, in a positive feedback action. Furthermore it 
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activates coagulation factor XIII, which cross-links the fibrin monomers, thus reinforcing the initial 
fibrin clot (Figure 3). In addition to its activity in coagulation cascade, α-thrombin promotes platelet 
aggregation [72, 74, 75].  
 
Figure 3 Schematic representation of the coagulation cascade process 
 
α-thrombin has the surprising property to switch its activity from a procoagulant to an anticoagulant 
one, through the binding to different macromolecules. Indeed, in complex with thrombomodulin α-
thrombin undergoes to a considerable conformational variation and loses its platelet activating and 
protease activities. Furthermore it becomes able to activate protein C, which in turn inhibits the 
formation of factors V and VIII. This process is very important in the normal physiological state, 
because normal endothelial cells produce thrombomodulin that binds any circulating thrombin, thus 
preventing clot formation in undamaged vessels [74].  
The thrombin capability to perform many different functions depends on its ability to recognize a large 
variety of substrates, inhibitors and cofactors. This ability is finely regulated by the binding of several 
ligands that allosterically modulate the substrate specificity of the enzyme, thereby rendering it capable 
of selecting its distinct substrates and cofactors in the opposite procoagulant and anticoagulant 
pathways[72, 74, 76]. 
The crystal structure of α-thrombin indicated the typical serine protease fold, composed of two 
adjacent β-barrels, which line a deep cleft where the characteristic serine-histidine-aspartate catalytic 
triad (Ser195, His57 and Asp102, in α-thrombin) is placed. However, with respect to the other enzymes 
of the family, α-thrombin has long insertion loops that are crucial for the recognition of its different 
ligands and make its active site less accessible than those of other proteases [77, 78]. In ligand 
recognition an essential role is played by two positive patches on thrombin surface, placed on the 
opposite sides of the active site, named exosites I and II (Figure 4). 
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Figure 4 Cartoon representation of thrombin molecule (PDB code 1PPB). Residues of active site, exosite I and 
exosite II, shown as spheres, are coloured orange, green and cyan respectively 
 
Exosite I is the binding site of thrombin physiological substrate fibrinogen, therefore it is also known 
as the fibrinogen recognition site (FRE), and contains also hydrophobic patches, whereas exosite II 
contains only a very large number of positive residues and is the binding site of thrombin inhibitor 
heparin [72, 77-79]. 
Thrombin generation is closely regulated to locally achieve rapid haemostasis after injury, without 
causing uncontrolled systemic thrombosis. In the absences of efficient and timely thrombin generation, 
stable blood clots cannot form, resulting in haemorrhage [80]. Conversely, unregulated thrombin 
activity produces an excessive coagulation function, resulting in dissemination of the clot beyond the 
site of vessel damage. It can obstruct normal blood flow thus causing thrombosis.  
The capability of inhibiting and regulating thrombin activity in vivo by synthetic compounds is an 
important goal in prevention and treatment of clotting abnormalities. Thrombin inhibition can be 
achieved by different mechanisms [81]. An option is blocking its active site, through the binding of 
substrate analogues that form covalent bonds with thrombin catalytic residues, in this way the 
hydrolysis of both macromolecular and small substrates is prevented. Another mechanism is blocking 
the binding of macromolecular substrates to exosite I or even favouring the binding of thrombin to 
SERPINs (SERine Protease INhibitors), which irreversibly suppress thrombin activity. The last 
mechanism is that by which heparin acts: it binds thrombin exosite II and drives the formation of the 
complex between thrombin and a SERPIN, antithrombin [80, 82].  
Thrombin Binding Aptamer 
Many different thrombin inhibitors exist, including natural and modified peptides, glycosaminoglycans 
and even oligonucleotides. Amid these inhibitors, oligonucleotidic aptamers are particularly interesting. 
In 1992 a DNA 15-mer consensus sequence, 5'GGTTGGTGTGGTTGG3', which inhibits thrombin 
clotting activity at nanomolar concentration, was identified [55]. It was named thrombin binding 
aptamer, or TBA. TBA is a strong anticoagulant in vitro, acting on the two procoagulant function of 
thrombin, since it inhibits thrombin-catalyzed activation of fibrinogen and thrombin induced platelet 
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aggregation. Moreover it is able to bind both free and clot-bound thrombin [83, 84]. Nonetheless its 
promising properties as drug in anticoagulant therapies, TBA presents the trouble of a rather rapid 
degradation by nucleases in vivo. 
NMR solution structure of TBA revealed that it adopts a uni-molecular quadruplex structure, 
composed of two G-quartets and three loops, two TT loops on one side and a TGT loop on the 
opposite side (Figure 5). TT loops span narrow grooves, whereas TGT loop spans a wide groove [85, 
86]. 
 
Figure 5 Schematic representation of the structure adopted by TBA. Black arrowheads indicate 5'→3' polarity of 
the strands. Anti and syn guanines are depicted yellow and blue, respectively.  
 
The structure of thrombin-TBA complex was solved by X-ray crystallography at 2.9 Å resolution [87]. 
Although the central core of TBA is the same in the NMR and crystallographic models, some structural 
differences exist in the way these central bases are connected. In particular, because of the poor quality 
of diffraction data, the disposition of aptamer loops with respect to grooves was not clear and in the 
crystallographic model TGT loop spans a narrow groove, whereas TT loops span a wide groove (Figure 
6). 
 
Figure 6 Schematic representation of the two TBA models, NMR model (left) and crystallographic model (right): 
in the first one TT loops span narrow grooves, whereas TGT loop spans a wide groove, the opposite occurs in the 
second one 
 
In a second time the structure of the complex was re-determined with better diffraction data and by 
using the coordinates of the NMR structure of the 15-mer in the fitting procedure (NMR derived 
model) [88]. The two models refined to similar values of crystallographic R factor and Rfree and seemed 
to be equally correct. They differ for the orientation of TBA with respect to thrombin: the aptamer is 
rotated 180° about an axis between the two G-quartets. Thus in the pure crystallographic model TBA 
Part I - Introduction 
 
15 
 
interacts with thrombin exosite I by its TGT loop, whereas in the NMR-derived model by its TT loops 
(Figure 7). Thus, apart for establishing that the aptamer binds the enzyme through the loops, it 
remained fully uncertain the specific loop that is involved and the nature of the interactions that 
stabilize the complex. 
 
Figure 7 Representation of the two proposed models of thrombin-TBA complex: on the left the pure 
crystallographic one (PDB code 1HAP), and on the right the NMR-derived one (PDB code 1HAP). Thrombin 
molecule is shown as cartoon with heavy chain in green and light chain in violet. PPACK (orange) and TBA are 
shown in ball and stick. 
  
In the crystal, TBA also interacts with the exosite II of a second symmetry-related thrombin molecule 
(Figure 8) [88].  
 
Figure 8 TBA sandwiched between two thrombin molecules in the NMR-derived model 
 
These additional packing contacts raise the question of whether the recognition site of the aptamers on 
the thrombin molecule is the fibrinogen binding site or the heparin binding site, or both of them. The 
latter possibility has found credit on the basis of isothermal titration calorimetric data that were 
interpreted in terms of a complex in solution formed by two thrombin molecules and one aptamer [89]. 
However, more recent data support the 1:1 stoichiometry [90]. 
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Modified Thrombin Binding Aptamer 
A great effort has been devoted in the last years to development of new thrombin binding aptamers 
with improved pharmacological properties. As mentioned before, unmodified TBA presents some 
drawbacks, in particular a rather rapid digestion by endogenous nucleases. Thus several modified 
aptamers have been produced and characterized, including aptamers with modified residues [91], LNA 
(locked nucleic acid) [92, 93], 2’F-ANA (2’-deoxy-2’-fluoro-arabino nucleic acid) [94], isoguanine [90], 
acyclic thymidine nucleosides [95], or non-canonical linkages between contiguous residues, formacetal 
bonds [96] or 5’-5’ polarity inversion sites [97]. The latter strategy is particularly promising because it 
has been reported that polarity inversion sites confer an increased resistance to endogenous nucleases 
[98], allowing the use of natural monomers, whose metabolites should not be toxic for organism. At the 
same time it has been proved that oligonucleotides with polarity inversion sites are still able to adopt 
the quadruplex structure required for thrombin binding.  
A modified thrombin binding aptamer, with a 5'-5' polarity inversion site between thymine 3 and 4, 
named mTBA (Figure 9), was produced and amply characterized [89, 97].  
   
Figure 9 Comparison between a canonical 3’-5’ and a 5’- 5’ bond (on the left). On the right schematic 
representation of the structure adopted by mTBA. Black arrowheads indicate 5'→3' polarity of the strands, black 
circle represents the 5'–5' polarity inversion site. Anti and syn guanines are depicted yellow and blue, respectively 
 
mTBA presents some improved properties with respect to its unmodified counterpart: it is slightly 
more stable (Tm is 53°C and 58°C for TBA and mTBA, respectively) and has a higher thrombin affinity 
(Kb is 3x10
6 M and 4x107 M for TBA and mTBA, respectively). However its inhibitor activity is less 
than that of TBA, as assessed by prothrombin time tests [89]. mTBA structure was solved in solution 
by NMR: it folds as a uni-molecular G-quadruplex with a chair-like conformation, similar to that of 
unmodified TBA. Few differences are observed between the two molecules [97], but they do not 
provide a clear justification of their different properties.  
Despite its reduced inhibitory activity, mTBA represents a good starting point for the design of 
improved therapeutics. 
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Thesis purpose 
So far the rational design of aptamer based anti-thrombotic agents has been prevented by the absence 
of a clear knowledge of interactions between thrombin and TBA, due to the lack of an unambiguous 
and detailed structure of their complex. In this context the purpose of the present research work is the 
structural characterization by X-ray diffraction of the complex of human α-thrombin with mTBA and 
the rivisitation at higher resolution of the structure of α-thrombin with TBA.  
The initial part of this thesis job consisted in screening and optimization of crystallization conditions, in 
order to obtain large, well diffracting crystals of thrombin-mTBA and thrombin-TBA complexes. 
These crystals were then used for diffraction data collection. Complexes structures, solved and refined 
at high resolution, were analyzed and compared to each other, with the aim to clarify the doubts 
existing about the recognition between the molecules and the complex assembly and to justify the 
different properties deriving from the polarity inversion site. Moreover, in order to investigate the 
effect of ions on aptamer folding and binding to target enzyme, thrombin-TBA complex was 
characterized in two different conditions, in the presence either of potassium or sodium ions.  
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RESULTS AND DISCUSSION 
 
Aptamers folding 
Nucleotides conformational homogeneity was checked by circular dichroism measurements. The 
aptamers were dissolved in potassium or sodium phosphate buffer at pH 7.1, heated 10 minutes at 
85°C, then they were slowly cooled down to room temperature and stored at 20°C. After one night a 
small aliquot of each sample was diluted at 20 µM in order to record circular dichroism spectra.  
 
Figure 10 CD spectra of TBA-K (left) and TBA-Na (right) 
 
 
Figure 11 CD spectrum of mTBA 
 
The spectra are very similar to each other, despite the polarity inversion site of mTBA: they present two 
positive bands at 248 and 294 nm and a negative one at 267 nm (see Figure 10 and Figure 11). These 
characteristic signals indicate that each aptamer consists of at least two G-tetrads with an alternating 
anti and syn glycosidic conformation along each strand, they are typical for anti-parallel quadruplex 
structures [99, 100]. Slight differences exist between CD spectra of the two TBA samples: the spectrum 
of TBA-K is more resolved, suggesting that the potassium ion stabilizes the quadruplex fold better than 
sodium ion.  
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Crystal structures 
Overall structure and thrombin molecule  
After an extensive screening of crystallization conditions, good quality crystals of thrombin-mTBA and 
thrombin-TBA complexes have been obtained (Figure 12). The formers belong to the space group I222 
and diffract up to a resolution of 2.15 Å. Crystals of the complex between thrombin and TBA-K and 
TBA-Na are isomorphous, space group P1, and diffract up to a resolution of 2.05 Å and 1.80 Å, 
respectively. 
 
A    B  
Figure 12 Best crystals of thrombin-mTBA complex (A) and thrombin-TBA complex (B) 
 
 
In all cases the asymmetric unit contains one thrombin and one aptamer molecule (Figure 13).  
 
 
 
Figure 13 Overall structure of the thrombin-mTBA (A), thrombin-TBA-K (B) and thrombin-TBA-Na (C) 
complexes. The missing γ autolysis loop in B and C is marked with a black circle  
 
 
 
The final models of the complexes were refined to R-factor/Rfree values of 0.196/0.252, 0.182/0.234 
and 0.178/0.224, for thrombin-mTBA, thrombin-TBA-K and thrombin-TBA-Na, respectively. A full 
list of refinement statistics is reported in Table 1. 
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Table 1 Summary of refinement statistics for thrombin-aptamers complexes 
 
 Thrombin-
mTBA 
Thrombin-
TBA-K 
Thrombin-
TBA-Na 
Refinement Results    
Resolution limits (Å) 50.00-2.15 50.00-2.05 50.00-1.80 
Number of reflections used 
in the refinement (F>2σ (F)) 
23598 19447 26555 
No. of reflections in working set 22464 18499 25273 
No. of reflections in test set 1134 948 1282 
R/Rfree  0.196/0.252 0.182/0.234 0.178/0.224 
No. of protein atoms 2374 2266 2265 
No. of aptamer atoms 306 315 306 
No. of ligand atoms 44 44 44 
No. of water molecules 250 191 222 
No. of ions 2 6 7 
    
RMSD from ideal values    
Bond lengths (Å) 0.02 0.02 0.02 
Bond angles (°) 2.11 1.92 2.10 
    
Average B-factors (Å2)    
Protein, overall 18.29 30.55 25.74 
Main chains 17.03 28.84 23.98 
Side chains 19.52 32.18 27.41 
Ions, solvent and ligand atoms 28.49 39.83 36.78 
Aptamer atoms 25.90 40.79 38.12 
    
Ramachandran plot statistics    
Residues in the most favored regions 
(%) 
86.3 97.0 98.1 
Residues in the additionally allowed  
regions (%) 
13.7 2.2 1.9 
Residues in the generously allowed  
regions (%) 
- 0.7 - 
 
The polypeptide chain of thrombin is very well defined for the whole heavy chain (residues 16-247) and 
for residues 1H–14L of the light chain, in the case of thrombin-mTBA complex, whereas in both the 
thrombin-TBA structures it is well defined for the heavy chain (residues 16-246), with the exception of 
the γ-autolysis loop (residues 148-150), and for residues 1B-14K of the light chain. The light chain and 
the γ-autolysis loop are very flexible regions, whose conformation is usually found to be strongly 
affected by crystal packing: when intermolecular crystal contacts are missing these region are generally 
disordered and not visible in electron density maps, as happens in the present triclinic crystal form of 
thrombin.  
All residues in the refined structures, with the exception of two residues of a flexible loop in thrombin-
TBA-K, lie within "allowed" regions of the Ramachandran plot. These results are remarkable when 
compared with the quality of the old thrombin-TBA structures, PDB codes 1HAO and 1HAP [87, 88], 
for which only the 79.6% of residues are in favoured region, whereas the 17.9/16.0% lie in allowed 
region and the 2.6/4.4% in forbidden regions, for the structures 1HAO/1HAP respectively. 
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The quality of electron density maps is very high for all the models. As an example in Figure 14 omit 
Fo-Fc map in the N-terminal region of light chain calculated for each of the two dataset of thrombin-
mTBA complex is represented.  
 
Figure 14 Comparison of electron density maps in the N-terminal region of thrombin light chain (thrombin-
mTBA complex) calculated with data collected from thin crystals at 2.99Å (up) and from best crystals at 2.15 Å 
(down). See methods section and Table 7 for further details 
 
As expected, the final model maintains all the structural features of the uncomplexed molecule. The 
thrombin structure is very similar in all three models (after superposition of all Cα atoms the RMSD is 
in the range 0.32-0.56 Å) and to the PPACK-inhibited enzyme (PDB code 1PPB [77]) (the RMSD is 
0.67 Å, 0.81 Å and 0.59 Å for the complex with mTBA, TBA-K and TBA-Na, respectively). The largest 
deviations are localized in more flexible regions, such as the light chain, and in particular its N- and C- 
terminal tails. With respect to thrombin-TBA structures, thrombin in complex with mTBA is more 
ordered, thanks to crystal packing interactions. In particular the thrombin light chain is placed between 
two symmetry related complexes and interacts at the N-terminal tail with phosphates from residues 14 
and 15 of the mTBA and at the C-terminal end with the light chain of a second thrombin molecule, 
whereas the γ autolysis loop (residues 149A-149L) is involved in hydrophobic interactions with residues 
89 -92 of a symmetry related molecule. Moreover several hydrogen bonds, direct or mediated by water 
molecules, connect the two thrombin molecules. This pattern of interactions is comparable to that 
observed in PPACK-thrombin crystal structure (PDB code 1PPB [77]). 
The architecture of the active site is strictly conserved among all the PPACK inhibited thrombin 
structures and the density corresponding to the inhibitor is very well defined in the present models 
(Figure 15).  
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Figure 15 Omit Fo-Fc electron density map (4.5 σ level) of the PPACK inhibitor and active site residues of 
thrombin-TBA-Na. 
 
PPACK (D-Phe-Pro-Arg-chloromethylketone) forms two covalent bonds with Oγ of Ser195 and Nε of 
His57, Pro is encapsulated in a hydrophobic pocket formed by several thrombin residues and Phe of 
PPACK itself and finally Arg engages salt bridges with Asp189.  
Another important region is the sodium binding site, located in the 217-225 loop, since this ion plays a 
key role in modulating thrombin allostery and strongly affects thrombin structure. The analysis of the 
positive difference peaks generated by an Fo-Fc map and of the coordination geometry clearly indicates 
the presence of sodium ion near the segment 220-225, in agreement with other thrombin models 
deposited in the PDB. The ion is hexa-coordinated with octahedral geometry, the six ligands are four 
water molecules (placed in a range from 2.2 Å to 2.9 Å apart from Na+) and the carbonilic oxygen 
atoms of Lys224 and Asp221A (Figure 16). It is notable that the sodium ion is present in all the 
structures: thrombin affinity for sodium is so high that the ion, already present in the protein sample, 
either cannot be removed by dialysis against potassium buffers or thrombin binds Na+ from 
crystallization solution.  
 
 
Figure 16 Omit Fo-Fc electron density map (4.5 σ level) of the sodium ion in thrombin-mTBA. Water molecules 
and thrombin residues that form its coordination sphere are also shown 
 
Furthermore in both the thrombin-TBA structures, two zinc ions from the crystallization solution bind 
residues on thrombin surface and are involved in packing contacts. Both the ions have tetrahedral 
coordination, typical for Zn2+: the first one binds His119, Asp1A, Asp222 of a symmetry related 
molecule and a water molecule, the second one binds Asp60E, Asp125 of a symmetry related thrombin 
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molecule and two chloride ions, in turn bound to a bridging water molecule (Figure 17). The tetrahedral 
coordination of the first zinc site is regular (metal-ligand distances in the range 1.8-2.1 Å), whereas it is 
more distorted in the second one. Indeed zinc-chloride distances are longer than zinc-oxigen ones. 
A                               B  
Figure 17 Representation of the two zinc sites on thrombin surface. The two symmetry related thrombin 
molecules are depicted purple and yellow, respectively. Chloride ions in second zinc site (B) are shown in green 
 
Modified and unmodified thrombin binding aptamers 
Electron density maps corresponding to aptamer molecules are clear and continuous, and have allowed 
the building of the whole TBA and mTBA in the three structures, with the exception of Thy9 base of 
TBA-Na and Thy7 base of mTBA.  
In particular in the case of mTBA electron density corresponding to the polarity inversion site is 
perfectly defined (Figure 18). 
 
Figure 18 Omit Fo-Fc electron density map (4.0 σ level) of the two mTBA residues (Thy3 and Thy4)  involved in 
the polarity inversion site 
 
X-ray analysis of aptamers in complex with thrombin reveals that all the molecules fold as chair-like 
quadruplexes with two stacked G-quartets, the TGT loop on one side and the two TT loops on the 
other side. It must be underlined that TBA adopts almost the same structure both in the presence of 
sodium or potassium ion, as also suggested by CD spectra. TBA possesses alternated antiparallel 
strands, and the disposition of glycosidic bond angles along the strands determines an alternation in 
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each G-tetrad of anti and syn guanines and in the quadruplex of wide grooves (between strands Gua1-
Gua2/Gua14-Gua15 and Gua5-Gua6/Gua10-Gua11) and narrow grooves (between strands Gua1-
Gua2/Gua5-Gua6 and Gua10-Gua11/Gua14-Gua15). TT loops span narrow grooves, whereas TGT 
loop spans a wide groove. This result indicates that between the previously proposed TBA models, the 
correct one is the NMR model [85, 86]. Differences between modified and unmodified aptamers are 
observed in strands orientation and grooves dimension. Because of the presence of the polarity 
inversion site, mTBA possesses three strands parallel to each other and the fourth one oriented in the 
opposite sense. Along the chain, the bases forming the G-quartets have alternating syn/anti 
conformations, as happens in TBA, but, because of the inversion site, within the two tetrads the 
arrangement of the guanines is anti-anti-syn-anti and syn-syn-anti-syn, respectively. These sets of glycosidic 
bond angles give rise to two medium grooves (between Gua1-Gua2/Gua5-Gua6 and Gua1-
Gua2/Gua14-Gua15), one narrow groove (between Gua10-Gua11/Gua14-Gua15) and a wide groove 
(between Gua5-Gua6/Gua10-Gua11). These features are also found in the solution structure of free 
mTBA [97].  
A deeper insight into the quadruplex structures was obtained by defining average G-quartet planes and 
calculating with respect to them the RMSD of guanine atoms and the angle that each guanine residue 
describes. Furthermore distance and angle between the two average G-tetrad planes were also 
calculated. Results obtained are reported in Table 2. 
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Table 2 Comparison among the core structures of the different models of mTBA and TBA 
 
   
RMSD of Gua 
atoms with 
respect to the 
average tetrad 
plane (Å) 
Angle 
between the 
two average 
tetrad planes 
(°) 
Distance 
between the 
two average 
tetrad planes 
(Å) 
Angle between guanine plane 
and the average tetrad plane (°) 
mTBA 
X-ray 
model 
Tetrad 
1 
0.25 
0.8 3.40 
Gua1 
2.3 
Gua6 
11.4 
Gua10 
11.3 
Gua15 
8.9 
Tetrad 
2 
0.22 
Gua2 
8.0 
Gua5 
2.7 
Gua11 
10.6 
Gua14 
6.3 
NMR 
model 
Tetrad 
1 
0.37 
1.5 3.70 
Gua1 
14.7 
Gua6 
10.6 
Gua10 
10.3 
Gua15 
-17.1 
Tetrad 
2 
0.38 
Gua2 
-8.0 
Gua5 
10.4 
Gua11 
-20.9 
Gua14 
11.6 
TBA 
K+ 
Tetrad 
1 
0.35 
0.6 3.45 
Gua1 
8.9 
Gua6 
12.2 
Gua10 
8.0 
Gua15 
13.5 
Tetrad 
2 
0.39 
Gua2 
9.2 
Gua5 
4.5 
Gua11 
12.8 
Gua14 
7.8 
Na+ 
Tetrad 
1 
0.39 
0.8 3.40 
Gua1 
10.0 
Gua6 
12.0 
Gua10 
11.5 
Gua15 
15.8 
Tetrad 
2 
0.44 
Gua2 
10.1 
Gua5 
6.9 
Gua11 
13.7 
Gua14 
7.6 
1HAO 
Tetrad 
1 
0.35 
1.6 3.66 
Gua1 
3.3 
Gua6 
12.6 
Gua10 
2.0 
Gua15 
17.6 
Tetrad 
2 
0.36 
Gua2 
14.2 
Gua5 
10.9 
Gua11 
11.8 
Gua14 
4.6 
 
These results clearly show that in our three models the two G-tetrad planes are more parallel to each 
other. Apart from this, all the TBA structures are comparable as far as a single G-tetrad is concerned. 
In the case of mTBA more marked differences exist between our crystallographic model and the NMR 
one: in the latter structure quartet planes are more distorted. 
Larger differences can be observed in the loops of the two mTBA structures (Figure 19). In particular, 
the TGT loop adopts a different conformation: Gua8 and Thy9, which in the NMR model stack on the 
quartet formed by Gua1, Gua6, Gua10 and Gua15, loose the interaction with the tetrad, the bases 
become more parallel to each other and make direct stabilizing interactions. This conformational 
variation determines the expulsion of Thy7 from the wide groove, so that the base becomes more 
exposed to the solvent and disordered. With respect to free mTBA, the two TT loops move away from 
each other, the direct hydrogen bond between Thy4 and Thy13 is lost with the insertion of a bridging 
water molecule. These two bases lie on a plane that stacks on the second G-quartet formed by Gua2, 
Gua5, Gua11 and Gua14. Finally, Thy3 adopts a conformation that is completely different in the two 
models.  
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Figure 19 Comparison between the X-Ray (A) and the NMR (B) structures of mTBA. Residues that adopt 
different conformations in the two models are depicted in magenta. 
 
The movement of TT loops upon thrombin binding observed for mTBA is found in both the 
structures of TBA with respect to the unbound NMR model, furthermore the Thy4-Thy13 pair 
described above is also present in our crystal structures of TBA. 
The detailed analysis of oligonucleotide structures highlights some interesting features, never stressed 
before. Whereas in the structures of nucleic acids the C8 of purine in anti conformation has been 
reported to form weak intra-residue C-H•••O interactions with the O5' [101-103], in our models inter-
residue contacts between C8 and O4' are observed. A brief analysis of other quadruplex structures 
(PDB codes: 2AVH, 1JPQ, 1I34) shows that this type of interaction is not unusual in antiparallel 
quadruplex, where guanine residues with syn and anti conformations are alternated along the strand. On 
the contrary it is absent in parallel structures with all anti guanines. This interaction is likely to 
contribute to some extent to the stability of the G-quadruplex.  
Examination of the Fo-Fc difference map clearly shows the presence of an ion sandwiched between the 
two G-quartets of the three aptamer structures (Figure 20). Alkaline ions (usually K+ or Na+) 
coordinated to the buried carbonyl oxygens of the nucleotide bases are crucial for the stabilization of 
quadruplex structures, since they balance the strong negative electrostatic potential created by the 
guanines O6 oxygen atoms [104]. In the case of mTBA and TBA-K, the residual electron density is 
spherical and almost equidistant from the eight O6 atoms of the guanines of the tetrads. The ion, 
placed between the two quartets, has a coordination number of eight, at distances from the O6 atoms 
ranging between 2.68 and 2.90 Å, in a distorted anti-prism geometry. This coordination geometry is 
typical for potassium ion [16], whereas sodium ion often lies on or close to the quartet plane [17, 19]. 
Moreover, it is well known that potassium, because of its higher ionic radius, is more efficient than 
sodium ion in stabilizing quadruplex structures [105]. Altogether these findings strongly suggest that the 
density seen in the residual map is produced by a potassium ion bound to mTBA and TBA-K. 
Unexpectedly, in the case of the thrombin-TBA-Na structure the residual electron density is placed 
between the G-quartets, and not on or close to them as expected for sodium ions. However it has an 
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elliptical and not spherical shape. Therefore two distinct conformations of sodium ion, with the same 
atomic occupancy, were modelled.  
 
Figure 20 Omit Fo-Fc electron density map (6.0 σ level) of the ion stacked between aptamer quartets of mTBA 
(A), TBA-K (B) and TBA-Na (C) 
 
This difference could be due to the different ionic radius of Na+ and K+. The larger potassium ion fits 
better in the cavity lined by the guanine residues and occupies a unique site that is equidistant from the 
two planes, whereas for the smaller sodium ion two different positions are possible.  
These results underline the importance of good quality high resolution diffraction data: indeed in the 
previous crystallographic model of TBA no ion was identified in the structure. Furthermore 
interactions between quadruplex and positive ions are not directly visible in NMR structures. 
Special attention has been devoted to investigate the nucleotides water interactions that are decisive for 
stability, dynamics, and recognition, since this is another structural feature not directly derivable from 
NMR. The high resolution of the diffraction data gives the opportunity to study in details the 
organization of the water molecules bound to the aptamers, particularly in the four grooves. In these 
regions water molecules arrange themselves in a continuous network of hydrogen bonds, linking the 
backbone and the bases of the quadruplex. 
It has been previously observed that water molecules are preferentially placed close to N2 and C8 
atoms of guanines in G-quadruplex [106, 107]. This feature is confirmed in the three aptamers 
structures. Moreover in both TBA and mTBA a conserved network of sequential N2-water-water-C8 
hydrogen bonds connecting adjacent strands is present, in particular in both wide and narrow grooves 
of TBA and in the narrow groove and in one of the two medium grooves of mTBA. New and less 
regular patterns of hydration, involving N2, N3 or backbone oxygens and a greater number of water 
molecules between adjacent strands, are observed in TBA and in the wide groove and in the other 
medium groove of mTBA. Thymine bases, being primarily involved in the binding with thrombin, are 
less hydrated than guanines in all the models. The non-conventional binding of waters to the C6 atom, 
observed, for example, for thymines of the quadruplex of Oxytricha nova telomeric sequence [17, 19] or 
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for all thymines of B-DNA [108], in the case of TBA and mTBA is marginal and involves only Thy9 of 
TBA-K and Thy4 of mTBA. Non conventional hydrogen bonding of water to methyl group of 
thymines is preferred in both the aptamers. This rich pattern of hydration involves both the four 
grooves and the three loops and it is likely to play a key role in maintaining the loop conformation.  
Some similarities are observed between the two TBA models and differences with respect to mTBA. 
For example, concerning the TGT loop, it adopts the same conformation in TBA-K and TBA-Na, with 
Thy7 and Gua8 stacked on the tetrad formed by Gua1, Gua6, Gua10, Gua15. This conformation is 
further stabilized by a water molecule interacting to the O6 atoms of Gua6 and Gua10, the N3 atom of 
Thy7 and the N7 atom of Gua8 (Figure 21).  
   
Figure 21 Side view (left) and top view (right) of the TBA-Na TGT loop stacking on G-tetrad formed by Gua1, 
Gua6, Gua10, Gua15 and the water molecule interacting with Thy7, Gua8, Gua6 and Gua10 
 
This water molecule is absent in the mTBA structure, whose TGT loop adopts a different 
conformation (described above).  
Furthermore in both the TBA models a water molecule links the phosphate groups of Thy13-Gua11 
and Thy4-Gua2, blocking the position of the two thymines. Residues Thy3 and Thy12 are more mobile 
(B factor values are higher with respect to other TBA residues) and indeed they assume two slight 
different positions in TBA-Na and TBA-K.  
Architecture of the complex 
The crystallographic structures of the complexes definitely show that the aptamers interact with 
thrombin exosite I by their TT loops, with a further contribution  of Gua2 backbone in the case of 
mTBA. This feature is in line with the NMR derived model, proposed by Padmanabhan et al. in 1996 
[88]. It must be underlined, however, that in our structures different binding modes are observed for 
TBA and mTBA that differ by a 180° rotation of the aptamer with respect to thrombin (Figure 22). 
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Figure 22 Comparison between the two binding modes found for mTBA (on the left) and TBA (on the right) 
 
Notably, in the old model (1HAO) TBA interacts with thrombin similarly to mTBA. 
It should be stressed that, apart from the TGT loop, TBA has an approximate twofold symmetry 
around the helix axis, whereas this is not true for mTBA, because of  the inversion site. As the TGT 
loop is far from the protein binding site, two practically equivalent binding modes are allowed to TBA. 
Indeed, a deeper analysis of  aptamers-protein interactions shows that most of  them are preserved in 
both binding modes, with the only difference that they involve aptamer residues related by the twofold 
symmetry. 
Thrombin-aptamers interactions 
Upon binding the aptamer undergoes to a slight structural rearrangement, whereas the thrombin 
molecule strictly retains its original structure (as observed in the PPACK-inhibited molecule, PDB code 
1PPB [77]), except for the flipping of the peptide bond between Arg77A and Asn78. In the free 
enzyme residues 77A-79 are involved in a type I β-turn, which upon flipping converts in a type II β-
turn. In this new arrangement the residue in position i+3 of the turn (Asn78) adopts a conformation in 
the left-handed α-helical (Lα) region of Ramachandran map that is not a favoured region for branched 
residues, although  asparagine is often found to adopt the Lα conformation [109]. This modification of 
the protein appears to have a functional role, as it optimizes the contacts with the bound aptamer: the 
carbonyl oxygen of Arg77A is hydrogen bonded to the N1 and N3 atoms of TBA Thy4 or mTBA 
Thy13 (Figure 23).  
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Figure 23 The 77-79 β-turn of thrombin-mTBA (green) and PPACK-thrombin (grey). Interactions between O 
atom of Arg77A and N1 and N3 atoms of Thy13 in thrombin-mTBA complex are also shown 
 
Interactions between aptamers and thrombin are both hydrophobic and hydrophilic. As an example in 
Figure 24 and Figure 25 are represented some of them for TBA-K and mTBA, respectively. 
 
 
 
Figure 24 Examples of thrombin-TBA-K interactions. On the left disposition of Thy3 with respect to hydrophobic 
thrombin residues, on the right hydrogen bonds involving Thy4 
 
 
Figure 25 Examples of thrombin-mTBA interactions. On the left disposition of Thy3 with respect to hydrophobic 
thrombin residues, on the right hydrogen bonds involving Thy4  
 
A detailed summary of interactions between thrombin and aptamers is reported in Table 3 and Table 4. 
The analysis of thrombin-aptamer interfaces shows that some protein residues are involved in the 
aptamer binding in all the complexes (Arg75, Tyr76, Arg77A and Ile79), other residues bind specifically 
mTBA (Leu65 and Ile82) or TBA (His71 and Tyr117) (Figure 26).  
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Figure 26 Cartoon representation of thrombin with residues involved in aptamer binding represented as spheres. 
Residues that bind both aptamers are coloured blue, those that bind only TBA are coloured orange, those that 
bind only mTBA are coloured green 
 
Finally some slight differences exist between the thrombin-TBA-Na and thrombin-TBA-K interfaces. 
For example TBA-Na, but not TBA-K, is in contact with Ile24; on the contrary hydrophobic 
interaction with Asn78 observed in the case of thrombin-TBA-K is missing in thrombin-TBA-Na. 
 
Table 3 Polar interactions (hydrogen bonds and salt bridges) between thrombin and aptamers  
 
Thrombin-mTBA Thrombin-TBA-K Thrombin-TBA-Na 
mTBA 
residue 
Thrombin 
residue 
TBA-K 
residue 
Thrombin 
residue 
TBA-Na 
residue 
Thrombin 
residue 
Gua2 (O2P) 
Arg77  
(NH1, NH2) 
- - - - 
- - Thy3 (O4) His71 (ND1) Thy3 (N3) Glu77 (OE2) 
Thy4 (O4’) Tyr76 (N) Thy4 (O4) Arg75 (NH2) Thy4 (O4) 
Arg75  
(NH1, NH2) 
Thy4 (O2) Arg75 (NH2) Thy4 (O2) Arg77A (NH1) Thy4 (O2) Arg77A (NH1) 
Thy4 (O4) Arg77A (NH1) Thy4 (N1) Arg77A (O) Thy4 (N1, N3) Arg77A (O) 
- - Gua5 (O4') Arg77A (NH2) Gua5 (O4') Arg77A (NH2) 
Thy12 (N3) Glu77 (OE2) - - - - 
Thy13 (O4) 
Arg75  
(NH1, NH2) 
Thy13 (O2) Arg75 (NE, NH2) Thy13 (O2) Arg75 (NH2) 
Thy13 (O3’) Asn78 (ND2) Thy13 (O4’) Tyr76 (N) Thy13 (O4’) Tyr76 (N) 
Thy13 (N1) Arg77A (O) Thy13 (N3) Tyr76 (O) Thy13 (N3) Tyr76 (O) 
Thy13 (N3) Arg77A (O) - - - - 
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Table 4 Hydrophobic interactions between thrombin and aptamers 
 
Aptamer residue Thrombin residue 
 Thrombin-mTBA Thrombin-TBA-K Thrombin-TBA-Na 
Thy3 Tyr76, Leu65, Ile82 His71, Ile79, Tyr117 Ile24, Ile79, Tyr117 
Thy4 Tyr76 Asn78, Ile79 Ile79 
Thy12  Ile79 - Tyr76 
Thy13 Asn78, Ile79 Tyr76 Tyr76 
 
Furthermore, thanks to the good quality of the electron density maps, several water-mediated 
interactions between aptamers and thrombin were also identified. Some contacts that are direct in the 
case of TBA are water mediated for mTBA (for example those with His 71 or Tyr117), in other cases 
water mediated interactions are similar for both the modified and unmodified aptamers (such as those 
with Gly25, Thr74 and Gly69) and finally some of them are observed only for one of the two aptamers 
(Lys81 and Ser115 for mTBA, Ser27 and Lys70 for TBA). 
Comparison among thrombin-aptamer and other protein-DNA complexes 
In order to obtain a deeper characterization of thrombin-mTBA and thrombin-TBA complexes, several 
interface parameters, including the buried surface area (ΔASA), the “gap volume index”, the number 
and type of residues at the interface, the contribution to the interface by polar, non-polar and neutral 
atoms, were calculated and compared with values obtained for the old thrombin-TBA complex (PDB 
code 1HAO) and with mean values of these parameters obtained using a non-redundant dataset of 25 
protein-DNA complexes (Table 5).  
Notably, the thrombin-aptamers interface is much smaller than that generally found in protein-DNA 
complexes, it contains an unusual large number of non-polar atoms and it is constituted also by 
residues with a low propensity to bind nucleic acids, such as leucine, isoleucine and glutamic acid 
residues [110]. These features are observed for both mTBA and TBA. A remarkable feature of 
thrombin-aptamers interface is tight packing. The surface complementarity index (Sc) value obtained is 
one of the highest observed for protein-DNA complexes. On the contrary a particularly small value is 
obtained for the old thrombin-TBA complex. This could indicate a worse binding mode or could 
depend on the low accuracy of the old structure. It should be underlined that in thrombin-aptamers 
complexes the typical features of aptamer-target interfaces are observed: a particularly small interface 
area characterized by an excellent shape complementarity and a high number of intermolecular 
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interactions. Indeed it is peculiar that aptamers realize high affinity binding to their target thanks to a 
tertiary structure, which optimizes shape complementarity and intermolecular contacts [64]. 
It is interesting to note that some differences exist between thrombin-TBA-Na and thrombin-TBA-K 
at the protein-aptamer interface. The first structure is characterized by a larger buried surface area, a 
higher number of interface residues and intermolecular interactions. The binding affinity of mTBA and 
TBA to thrombin has been characterized by ITC measurements in a potassium buffer (10 mM 
potassium phosphate pH 7, 70 mM KCl, 0.1 mM EDTA) [89], whereas a successive ITC study has 
investigated the thrombin-TBA recognition in a sodium buffer (50 mM sodium citrate pH 6.5, 200 mM 
NaCl, 0.1% PEG 8K) [90]. Dissociation constant values obtained for TBA are comparable (Kd is ≈300 
nM in potassium buffer and ≈100 nM in sodium buffer). To verify whether the observed differences 
between the two new thrombin-TBA structures correspond to a different binding affinity, a new 
calorimetric parallel analysis, in which the only variable is the type of cation present in solution, is 
necessary. 
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Table 5 Protein interface properties 
 
 
Thrombin-
mTBA 
Thrombin-
TBA-K 
Thrombin-
TBA-Na 
Thrombin-TBA 
(1HAO) 
Protein-DNA 
complexes * 
Sequence segmentation 4 5 5 5 7 (4) 
Δ ASA (Å
2
) 570 445 502 462 1320 (495) 
Δ %ASA 4.8 3.8 4.4 4.0 13 (7) 
Atoms in Interface 60 39 48  40 122 (51) 
% Polar Atoms 
Contribution to Interface 
24.3 26.3 23.7 25.0 30 (7) 
% Non-Polar Atoms 
Contribution to Interface 
54.2 33.1 41.9 38.0 30 (11) 
% Neutral Atoms 
Contribution to Interface 
45.5 40.1 34.0 37.7 40 (9) 
Residues in Interface 15 10 13 12 43 (20) 
% Polar Residues in 
Interface 
46.7 50.0 53.8 58.3 37 (10) 
% Non-Polar Residues in 
Interface 
33.3 20.0 30.8 25.0 28 (9) 
% Charged Residues in 
Interface 
20.0 30.0 15.4 16.7 35 (9) 
Hydrogen Bonds 11 10 11 2 21 (9) 
Hydrogen Bonds (/100 Å
2 
ΔASA) 
1.9 2.2 2.2 0.5 1.6 (0.4) 
Bridging Water Molecules 4 0 3 0 17 (10) 
Bridging Water Molecules 
(/100 Å
2 
ΔASA) 
0.7 0 0.6 0 1.3 (0.7) 
Gap Volume (Å
3
) 2710 2281 2808 2997 7408 (3050) 
Gap Volume Index (Å) 2.38 2.6 2.8 3.49 3.0 (1.0) 
Sc 0.73 0.72 0.76 0.56 0.65 (0.05) 
 
*properties were calculated from a non-redundant dataset of 25 protein-DNA complexes belonging to different protein-
structure families with resolution better than 2.5 Å.  
 
Stoichiometry of the thrombin-aptamer complexes  
Once defined that protein-aptamer interactions involve exoxite I of thrombin and the TT loops of the 
aptamers, we analysed the crystal packing of the new and the old thrombin-aptamers complexes. 
Although these complexes have different crystal packing, the aptamers in all cases interact with 
symmetry related thrombin molecules by their TGT loop. However, these packing contacts differ from 
one complex to the other (Figure 27).  
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Figure 27 Comparison between the putative 2:1 thrombin-aptamers complexes (mTBA: green, TBA-Na: purple, 
TBA-K: orange and TBA-1HAO: cyan) 
 
In the old thrombin-TBA structure the TGT loop interacts extensively with the exosite II of the 
second molecule. In the case of mTBA the additional packing interactions of the TGT loop are far 
away from the exosite II and are limited to Thy9 that makes a cation-π interaction with Arg97, two 
hydrogen bonds with Glu97A, which in turn is hydrogen bonded to Gua15. In our structures of the 
TBA complexes, the TGT loop loosely interacts with two symmetry related thrombin molecules; only 
for one of them one residue of the exosite II is marginally involved . In all cases, these additional 
packing contacts are weaker and bury a much smaller surface area with respect to that involving the 
loop TT and exosite I. Details are reported in (Table 6). These observations suggest that the 
interactions involving thrombin regions distinct from exosite I are aspecific ionic contacts, that result 
from crystal packing, and do not imply a second binding site for a putative 2:1 complex in solution. 
These findings are in agreement with the more recent ITC data ([90]). In conclusion it is reasonable to 
say that the complex in solution has a 1:1 stoichiometry maintained by a specific recognition of the 
aptamer TT loops by the thrombin exosite I. 
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Table 6 Comparison among thrombin-aptamer interfaces in crystal structures of thrombin-TBA-K, thrombin-
TBA-Na, thrombin-mTBA, thrombin-TBA-1HAO 
 
  Buried Surface Area (Å2)  % Buried Surface Area 
Thrombin-TBA-K 
Exosite I 445 3.8 
TBA-sym1 280 2.4 
TBA-sym2 204 1.7 
Thrombin-TBA-Na 
Exosite I 502 4.4 
TBA-sym1 270 2.3 
TBA-sym2 148 1.3 
Thrombin-mTBA 
Exosite I 570 4.8 
mTBA-sym 248 2.1 
Thrombin-TBA 
(1HAO) 
Exosite I 462 4.0 
TBA-sym 
(exosite II) 
468 4.1 
 
Furthermore, whereas in the old thrombin-TBA complex model interactions at the second interface 
extensively involve thrombin exosite II, in the case of mTBA-sym and TBA-sym1 the binding site is 
placed far away from this exosite, and in the case of TBA-sym2 it marginally involves just one exosite II 
residue. These observations suggest that the interactions involving thrombin regions distinct from 
exosite I are aspecific ionic contacts, that result from crystal packing, and do not imply a second 
binding site for a putative 2:1 complex in solution. These findings are in agreement with the more 
recent ITC data [90]. In conclusion it is reasonable to say that the complex in solution has a 1:1 
stoichiometry, maintained by a specific recognition of the aptamer TT loops by the thrombin exosite I. 
About the different biological properties of modified and unmodified aptamers 
An extensive comparison between thrombin-mTBA and thrombin-TBA structures has been performed 
with the aim to investigate the molecular bases of the different biological properties of the two 
aptamers. With respect to the old crystallographic model proposed by Padmanabhan et al.[88], the 
peculiar structure of mTBA determines the formation of a greater number of contacts with the enzyme, 
hides a larger buried surface area (570 vs 462 Å2 for mTBA and TBA respectively) and leads to an 
increased shape complementarity (the surface complementarity indexes Sc are 0.72 and 0.56 for mTBA 
and TBA respectively as reported in Table 5). The comparison of the three new crystal structures 
highlights new features: although number of interactions and Sc values are comparable, in all the cases 
a smallest buried surface area is present in complexes of thrombin with unmodified aptamer. 
Altogether these findings suggest that the polarity inversion site in mTBA produces a better fit of the 
aptamer at the thrombin exosite I and accounts for the higher thrombin affinity of mTBA as compared 
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to TBA. Furthermore these results agree with some thermodynamic features of the thrombin-aptamers 
recognition phenomenon: the complex formation is enthalpically driven and the higher thrombin 
affinity of mTBA derives from its larger favourable enthalpy. On the contrary a less adverse entropy 
contribute has been found for TBA [89]. This could be rationalized by noting that, thanks to its 
symmetry, two different binding modes are available to TBA and probably not to mTBA.  
Analysis of the crystal structures sheds lights also on the lower inhibitory activity of mTBA with respect 
to TBA. An important interaction found in the case of the unmodified aptamer involves His71, a 
residue that plays a key role in recognition of fibrinogen and inhibition of thrombin clotting activity by 
TBA [111]. This contact between His71 and Thy12 (or Thy3, depending from the two possible binding 
modes of TBA) is lost in the case of mTBA. The position of this histidine is the same in all the 
complexes, but the characteristic structure of mTBA causes a subtle reorganization of the region close 
to the thymine that determines the lost of the His71-Thy12 (Thy3) contact and the formation of a salt 
bridge between the side chain of Arg77A and the phosphate oxygen atom of Gua2, a base in close 
proximity due to the reversed polarity of the strand. In the thrombin-TBA complexes the aptamer 
backbone is far away from Arg77A, whose side chain is flipped in the opposite direction. This causes 
the slight conformational change of the 77-79 segment mentioned before. In all the complexes Ile79 is 
in hydrophobic contact with Thy12 (Thy3), however to preserve this interaction mTBA moves away 
from His71 (Figure 28). The absence of this direct interaction between aptamer and His71 could 
determine the lower anticoagulant activity of mTBA.  
     
Figure 28 Comparison between thrombin-mTBA (green) and thrombin-TBA-Na (orange) interactions at exosite I 
region. Interactions between TBA Thy12 and His71 and between mTBA Gua2 and Arg77A are explicitly shown. 
On the right a zoom on the His71-Thy3 contact is reported
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Aptamers are considered very promising anticoagulant agents. They typically exhibit high affinity and 
specific binding to their target protein, which should allow for therapeutic dosing at submicromolar 
levels reducing potential non-specific effects, they are supposed to be non-immunogenic and antidotes 
can be designed to control their pharmacologic activity [64]. Since α-thrombin is the key enzyme of the 
coagulation cascade, it represents an ideal target for anticoagulant therapeutics and, indeed, a few years 
ago the Phase I clinical trial of TBA was started [112]. Despite this encouraging scenario, up to now the 
rational design of new aptamer based anti-thrombotic agents has been prevented by the absence of a 
clear knowledge of interactions between thrombin and TBA, due to the lack of an unambiguous and 
detailed structure of their complex. In this context the complexes structures here presented are of 
particular interest, because they not only clarify unresolved questions about thrombin-aptamers 
interaction, but also suggest the molecular bases of the different properties of TBA and mTBA and 
furnish a good starting point for the rational design of new modified aptamers for use in anticoagulant 
therapies. Moving on from these observations it is possible to design modified aptamers that preserve 
both the interactions essential for inhibition and the stability against nucleases. In particular, the 
polarity inversion site could be inserted in the second TT loop, between Thy12 and Thy13. In fact a 
deeper analysis of thrombin structure shows that a hydrophobic pocket, composed by Ile24, His71 and 
Tyr117 is close to Thy12. The insertion of an inversion polarity site could cause a conformational 
variation in this TT loop, as observed for Thy3 of mTBA, that could bring the Thy12 base in 
hydrophobic contact with the three residues, Ile24, His71 and Tyr117. This could improve thrombin-
aptamer interactions with respect to unmodified TBA, thus preserving the high thrombin affinity of 
mTBA. At the same time a better interaction between Thy12 and His71 could be achieved, which 
should enhance aptamer inhibitory activity. Finally, in order to obtain the best compromise between 
thrombin affinity and inhibitory activity, the two polarity inversion types, 3'-3' and 5'-5, should be 
tested, because they should determine different loop conformations. 
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MATERIAL AND METHODS 
 
Thrombin-aptamers complexes preparation 
A similar protocol was utilized to prepare complexes of human α-thrombin with modified and 
unmodified aptamers. The human D-Phe-Pro-Arg-chloromethylketone (PPACK) inhibited α-thrombin 
was purchased from Haemtech and two different samples were prepared, changing the initial buffer to 
KCl or NaCl 0.75 M, using Centricon mini-concentrator and a refrigerated centrifuge. The protein 
concentration was determined spectrophotometrically, by UV absorption at 280 nm (ε280 = 66612 M
-1 
cm-1). Samples at 0.9 mg/ml (25 µM) protein concentration were quickly frozen at -20°C. 
TBA was purchased from Genosys, whereas mTBA, synthesized and purified as previously described 
[97], was kindly provided by prof. Antonio Randazzo. Stock solutions of aptamers were prepared 
dissolving lyophilized oligonucleotides in sodium (TBA-Na) or potassium (TBA-K and mTBA) 
phosphate buffer 10 mM pH 7.1 at a concentration of 2 mM. Oligonucleotides concentration was 
verified spectrophotometrically, measuring absorption at 260 nm and using the same molar extinction 
coefficient, ε260 = 147300 M
-1cm-1, for TBA and mTBA. The measurements have to be performed on 
single strand oligonucleotides, so all the samples were previously heated at 90°C and maintained at this 
temperature during the scan, in order to disrupt any folded structure. To induce the folding into 
quadruplex structure, nucleotide samples were heated for 10 minutes at 85°C and then slowly cooled 
down and stored one night at 20°C. Then aptamers folding was verified by circular dichroism 
measurements. CD spectra, in the 200-350 nm range, were recorded at a constant temperature of 20°C 
on a Jasco J-710 spectropolarimeter equipped with a Peltier type temperature control system (Model 
PTC-348WI). Once stated that aptamer assumed an antiparallel quadruplex fold, the complexes with 
thrombin were prepared by placing a twofold molar excess of aptamer on the frozen sample of 
inhibited thrombin and leaving the sample three hours at4°C. Then the samples were diluted and the 
buffer changed to potassium phosphate 50 mM pH 7.1 and KCl 0.1 M, for thrombin in complex with 
mTBA and TBA-K, or sodium phosphate 50 mM pH 7.1 and NaCl 0.1 M, for thrombin-TBA-Na. The 
thrombin-aptamers complexes were extensively washed to take off aptamer excess and finally 
concentrated to about 8 mg/ml using Centricon mini-concentrator and a refrigerated centrifuge. It was 
not possible to determine spectrophotometrically the complex concentration because thrombin and 
aptamer absorption bands are superposed and no well resolved peak is observed in the UV spectra. 
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Crystallization 
Thrombin-mTBA complex 
Initial crystallization trials of thrombin-mTBA complex were performed at 20°C replying the 
crystallization conditions found for thrombin-TBA complex [87] or other thrombin complexes [113, 
114], but none of these trial was successful. Therefore other crystallization experiments were done 
using the sparse-matrix sampling method. The screening was carried out using commercially available 
kits (Crystal Screen kits I and II and Index kit from Hampton Research) and performing the trials both 
by hand and by a Nanodispersion Robotic System, “Microlab Starlet Nanojet 8+1” by Hamilton Life 
Science Robotics, at the Istituto di Biostrutture e Bioimmagini of CNR. Bushes of thin and damaged 
crystals (Figure 29) grew from a crystallization condition consisting of polyethylene glycol 4000 25% 
w/v, ammonium sulphate 0.2 M, sodium acetate 0.1 M at pH 4.5.  
 
Figure 29 Crystal of thrombin-mTBA before optimization of crystallization conditions 
 
In order to obtain crystals suitable for diffraction data collection it was necessary to perform a minute 
optimization of the crystallization conditions. Initially the concentration of protein and of precipitant, 
the pH values and the nature of the buffer were fine-tuned, also performing the crystallization trials at 
different temperatures (4 and 20°C). Since none of these trials brought to a substantial improvement of 
crystal quality, a screen of polyethylene glycols and methyl substituted poly(ethylene) glycols with 
different molecular weights was also tried. Good results were obtained using PEG 20000. It was 
possible to collect diffraction data from these crystals, but the resolution was low (2.99 Å). Indeed 
crystals were still too thin and fragile and most of them broke down when touched with the loop. Thus, 
in order to avoid this problem, the effect of several additives was tested. In particular alcohols (ethanol, 
2-methyl-2,4-pentandiol, isopropanol, n-propanol, n-butanol, tert-butanol, glicerol), sugars (treaolose, 
sucrose and xylitol), and organic liquids (dimethylformamide, acetonytril, dimethylsolfoxide) were 
added to the crystallization mixture at concentrations ranging from 0.5% to 10% v/v.  
Eventually good quality crystals of the complex were obtained from a crystallization solution that 
contained polyethylene glycol 20000 20% w/v, ammonium sulfate 0.2 M, n-propanol 3%, sodium 
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acetate 0.1 M at pH 5.8. Crystals grew in few days by sitting drop vapor diffusion method at 20°C. The 
protein-to-reservoir solution ratio was 1:1 in 1 µl drops and protein concentration was 8 mg mL-1. 
Thrombin-TBA complexes 
The crystallization condition found for thrombin-mTBA complex was tested to grow thrombin-TBA 
complexes too, but only amorphous precipitates were obtained. Thus, also in this case, it was necessary 
to perform an extensive screening of crystallization conditions, using commercial kits and the automatic 
crystallization system. Two different promising conditions were identified, in which small and thin 
crystals, morphologically distinct, grew (Figure 30). The first solution contained polyethylene glycol 
8000 20% w/v, zinc acetate 0.2 M, sodium cacodilate 0.1 M pH 6.5, the other one consisted of MPD 
50% v/v, ammonium phosphate 0.2 M, Tris/HCl 0.1 M pH 7.5. 
 
Figure 30 The two crystal forms (on the left crystals grown from PEG, on the right those grown from MPD) of 
thrombin-TBA complex before optimization of crystallization conditions 
   
In order to improve crystal quality a minute optimization of these crystallization conditions was 
performed. The concentration of precipitants and salts and the pH values were fine-tuned. 
Furthermore crystallization trials were performed using both the hanging drop and the sitting drop 
techniques. Although crystals obtained by the first technique seemed to be better, they were particularly 
fragile and disordered. Eventually crystals of both the complexes were obtained by sitting drop vapour 
diffusion method, at a protein-to-reservoir solution ratio of 1:1 in 1 µl drops. The crystallization 
solution containing polyethylene glycol 8000 10-15% w/v, zinc acetate 50 mM, sodium cacodilate 0.1 
M pH 7.4 produced good crystals for both the samples of thrombin-TBA complex (thrombin-TBA-Na 
and -TBA-K). Furthermore, crystals of only thrombin-TBA-Na were obtained in MPD 53% v/v, 
ammonium phosphate 50 mM, Tris/HCl 0.1 M pH 7 (thrombin-TBA-Na_2) (Figure 31).  
 
Figure 31 Best crystals of thrombin-TBA-Na_2 grown from MPD 
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Data collection 
Diffraction data from thrombin-mTBA complex and thrombin-TBA complexes grown in PEG were 
collected in-house on a Saturn944 CCD detector. The X-ray radiation used was Cu Kα radiation from a 
Rigaku Micromax 007 HF generator. Diffraction data from thrombin-TBA complex grown in MPD 
were collected by using synchrotron light at ELETTRA, Trieste. After the addition of 25% glycerol to 
the harvesting solution, all crystals were flash-cooled at 100K in supercooled N2 gas produced by an 
Oxford Cryosystem and maintained at 100 K during the data collection.  
All the data were indexed, processed and scaled with HKL2000 [115]. Thrombin-aptamers crystals 
belong to three different space groups and diffract at different resolutions. Detailed statistics on data 
collection are reported in Table 7.  
Matthews coefficient calculation suggested the presence of a single thrombin molecule in the 
asymmetric unit of thrombin-mTBA and thrombin-TBA crystals grown from PEG, whereas three 
thrombin molecules should be in the asymmetric unit of the thrombin-TBA-Na_2 crystals. Due to their 
low resolution (2.8 Å), the diffraction data collected from these crystals have not yet been used for 
structure determination.  
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Table 7 X-ray data collection statistics for thrombin-aptamers complexes 
 
 Thrombin-TBA-K Thrombin-TBA-Na Thrombin-TBA-Na_2 
Thrombin-mTBA 
(low resolution) 
Thrombin-mTBA 
(high resolution) 
Space group P1 P1 P3(1) I222 I222 
Unit-cell parameters      
a (Å) 43.369 43.018 94.253 68.211 68.208 
b (Å) 45.299 44.716 94.253 111.171 110.574 
c (Å) 51.519 52.689 124.180 120.566 120.916 
α (°) 68.975 65.222 90.000 90.000 90.000 
β (°) 86.114 85.327 90.000 90.000 90.000 
γ (°) 69.662 69.970 120.00 90.000 90.000 
Resolution limits (Å) 50.00-2.05 
(2.12-2.05) 
50.00-1.80 
(1.86-1.80) 
50.00-2.80 
(2.90-2.80) 
50.00-2.99 
(3.10-2.99) 
50.00-2.15 
(2.23-2.15) 
No. of observations 537199 645846 615127 541181 817402 
No. of unique reflections 20850 28160 30359  25096 
Completeness (%) 94.5 (84.5) 90.9 (75.6) 99.2 (92.8) 92.0 (85.5) 99.1 (93.2) 
I/σ(I) 16.8 (2.6) 19.4 (2.8) 12.3 (2.1) 7.6 (3.7) 9 (3.0) 
Average multiplicity 5.0 4.2 4.6  4.5 5.2 
Rmerge (%) 8.8 (36.4) 6.8 (40.2) 12.1(35.4) 13.4 (27.4) 13.7(42.7) 
Mosaicity 0.8 1.2 0.8 0.9 0.6 
VM (Å3Da-1) 2.26 2.21 2.72  2.92 
Solvent content (%) 45.7 44.3 54.8  57.9 
  
Rmerge = ∑hkl∑i |Ii(hkl)-<Ii(hkl)>|/ ∑hkl∑i Ii(hkl), where Ii(hkl) is ith intensity measurement of the reflection hkl, including symmetry related reflections, and 
<Ii(hkl)> is its average.  
Values in brackets are for the highest resolution shell.
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Structure determination and refinement 
All the structures, solved by molecular replacement or Fourier analysis, were refined with CNS. At the 
end of refinement the geometry of all the protein structures were monitored using PROCHECK [116] 
and WHATCHECK [117] programs. 
Thrombin-mTBA complex 
The structure of thrombin-mTBA was solved using the program AMoRe [118] and the PPACK-
inhibited thrombin structures (PDB code 1PPB) as a search model. To avoid bias, inhibitor and water 
molecules were removed from the model. The correlation for the highest solution was 0.59, with an R 
factor of 0.36. The starting model was subjected to few cycles of rigid body refinement with CNS [119] 
in the resolution range 10.0-3.00 Å. This resulted in a model with R=0.327 and Rfree=0.338. Fourier 
difference maps, calculated with (Fo-Fc) and (2Fo-Fc) coefficients, showed continuous electron density 
in proximity of thrombin exosite I. The presence in these maps of two parallel planes allowed the initial 
fitting of the eight guanine residues of the mTBA core. The structure was subjected to several cycles of 
coordinate minimization and B-factor refinement. Each run was alternated with manual model building 
using O program [110]. Analysis of Fourier difference maps at following stages of refinement allowed 
the fitting of PPACK in the active site, the stepwise rebuilding of the whole aptamer molecule, the 
positioning of two ions, one stacked between aptamer quartets and the second one interacting with 
thrombin residues, of several water molecules, and finally the identification of an N-acetyl glucosamine 
residue linked to Asn60G of the heavy chain and absent in the initial search model. During these cycles 
the R and Rfree reduced to 0.250 and 0.295, respectively. Finally the resolution range was extended to 
include low resolution data and the bulk solvent correction was applied. The crystallographic R factor 
and Rfree for the final model in the resolution range 50.0-2.15 Å are 0.196 and 0.252, respectively. 
Definition of topologies and parameters for mTBA and PPACK molecules to be used in CNS 
refinement was particularly challenging. Concerning mTBA, CNS parameters for nucleic acids were 
modified in order to include the polarity inversion site and the reverse polarity of the segment Gua1-
Thy3. CNS topology and parameter files for the segment Gua1-Thy4 were calculated using the Prodrg 
(http://davapc1.bioch.dundee.ac.uk/prodrg/) server, then they were merged with default parameters 
and the correct connectivity between residues was obtained modifying by hand the input files. For what 
concern the inhibitor molecule, parameters for a fictitious ligand formed by PPACK and thrombin 
residues Ser195 and His57 to whom inhibitor is covalently bound were calculated using the Prodrg 
(http://davapc1.bioch.dundee.ac.uk/prodrg/) server. These files were used for PPACK molecule and 
to modify the default protein topology and parameter files for the side chain of amino acid residues 
involved in PPACK binding. Furthermore it was necessary to insert in the refinement input files a 
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specific patch to include the non-conventional covalent bonds between the side chains of thrombin 
residues and PPACK. 
Thrombin-TBA complexes 
The structure of thrombin-TBA-K was solved by the molecular replacement method using the program 
Phaser [120] of the CCP4 package and coordinates of inhibited thrombin derived from the structure of 
its complex with mTBA and coordinates of TBA derived from the structure of the thrombin complex 
(PDB code 1HAO) as search models. To avoid bias, PPACK, ions and water molecules were removed 
from model. A clear solution was obtained with a Z-score of 12.5 and an LLG of 1206. In a second 
moment diffraction data from thrombin-TBA-Na crystals were collected. Since crystals of the two 
complexes were isomorphous, it was not necessary to perform molecular replacement: the partially 
refined structure of thrombin-TBA-K was utilized as starting model for the other complex. Slight 
rearrangement of the complex assembly were taken in count performing several cycles of rigid body 
refinement of the initial model, treating TBA and thrombin as distinct rigid groups. 
A preliminary comparison between these structures and the other crystal form of the thrombin-TBA 
complex (PDB code 1HAO) showed that the orientation of the aptamer with respect to thrombin is 
different in the two cases. The analysis of Fourier difference maps, calculated with (Fo-Fc) and (2Fo-
Fc) coefficients, seemed to confirm the novel complex architecture for both thrombin-TBA-K and 
thrombin-TBA-Na. However, in order to be sure of the correctness of our structures, the whole TBA 
molecule was removed from the models and rebuilt stepwise: first of all the two G-quartets, then Thy 4 
and Thy 13, followed by Thy 3 and Thy 12 and finally residues of the TGT loop. A protocol similar to 
that described for thrombin-mTBA complex was used for refinement of thrombin-TBA complexes. 
Also in these cases, electron density maps were particularly clear and allowed the fitting of PPACK in 
the active site, the positioning of several ions, one stacked between aptamers quartets, one interacting 
with the same thrombin residues identified for thrombin-mTBA complex, and the others involved in 
packing interactions, of several water molecules, and the identification of the glycosilation site. After 
inclusion of low resolution data and bulk solvent correction, the crystallographic R factor and Rfree for 
the thrombin-TBA-K final model in the resolution range 50.0-2.05 Å are 0.182 and 0.234 respectively, 
whereas for the thrombin-TBA-Na final model, in the resolution range 50.0-1.80 Å, are 0.178 and 
0.224, respectively. 
Structural analysis of  aptamers and thrombin-aptamers complexes 
A deep characterization of aptamers structures was obtained compiling a program that defines the 
average G-quartet plane and calculates the RMSD of guanine atoms from this plane, the angle that each 
guanine residue describes with respect to the plane, the distance and the angle between the two average 
G-quartet planes. The characterization of hydration has been obtained identifying the networks of 
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water molecules with HBPLUS [121] and by visual inspection of the structure, whereas unconventional 
CH•••O hydrogen bonds have been identified using HBAT [122].  
Features of the protein-aptamer interfaces, including buried surface area, number and types of residues 
at the interface, and gap volume index, were calculated using the Protein-Protein Interaction Server 
(http://www.bioinformatics.sussex.ac.uk/protorp/). For comparison, the same parameters were 
calculated as average values from a non-redundant dataset of 25 protein-double stranded DNA 
complexes solved at a resolution better than 2.4 Å. The shape complementarity score, Sc, as defined by 
Lawrence and Colman [123], was calculated using the CCP4 package [124], opportunely modified to 
include nucleic acid parameters. For atomic groups in DNA, standard radii values as defined by 
Nadassy et al. were used [125]. Finally the molecular interactions between aptamers and thrombin 
molecules in the same or in other asymmetric units were found using the CCP4 package [124] (in 
particular the Contact program) and by visual inspection of the structure with O program.  
All the figures were generated using Pymol (http://pymol.org).  
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PROTEINS INVOLVED IN NUCLEIC ACIDS 
RECOGNITION: THE RIBONUCLEASE SYSTEM 
 
 
INTRODUCTION 
 
The Vertebrate Ribonuclease Superfamily 
One of the best known and most studied classes of nucleic acid binding protein is that of ribonucleases. 
Ribonucleases (RNases), which are enzymes catalyzing the hydrolysis of the phosphodiesteric bond of 
RNA, play a key role in metabolism of ribonucleic acid [126], operating between transcription and 
translation. In particular they are involved in RNA degradation, transformation of precursors into 
mature forms of RNA and production of short segments of regulator RNA. Other important biological 
functions ascribed to RNases are related to the control of gene expression, growth and cell 
differentiation, cell protection from the attack of pathogens and induction of apoptosis [127]. 
A well characterized subfamily is that of pancreatic like ribonucleases, whose prototype is the bovine 
pancreatic ribonuclease or RNase A. Pancreatic like ribonucleases are endoribonucleases that 
specifically cleave phosphodiesteric bonds with a pyrimidine base at the 3' end [126]. They usually act 
on single stranded RNA [128], but some members of the family are able to hydrolyze also double 
stranded RNA and DNA-RNA hybrid structures [129-131]. Among the signature features of this gene 
family, all active pancreatic-like ribonuclease coding sequences are initiated with a signal sequence, all 
mature proteins include six to eight appropriately spaced cysteines that form distinct disulfide bonds, 
and all include two catalytic histidines and a single lysine, the latter within an invariant sequence motif 
(CKXXNTF) [132]. As a rule, their coding sequences are found on a single exon [133]. 
Although the members of the family present primary sequences very different to each other, they share 
a common three-dimensional structure and catalytic site. In particular the “RNase fold” consists of 
three α-helices and two β-sheets, each composed of three antiparallel β-strands, arranged in a typical V 
shape with a deep cleft, where the active site is placed [134].  
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Figure 32 Cartoon representation of RNase A. Catalytic residues (His12, Lys41, His119) are also shown as ball and 
sticks. 
 
The catalytic centre, as mentioned before, is composed by two histidines, one located in helix I and one 
located in the C-terminal strand (respectively His12 and His119 in the RNase A numeration) and a 
lysine (Lys41 in RNase A). The catalytic mechanism consists of two steps: in the first one the 
imidazolium side chain of His12 acts as a base to extract a proton from the 2’-hydroxyl of the substrate, 
thus facilitating its attack on phosphorus atom. The acidic His119 side chain protonates the 5’-oxygen, 
facilitating the departure of the leaving group. In the second step, the enzyme catalyzes the attack on 
the 2’-3’-cyclic phosphodiester by a water molecule, producing a phosphate monoester on the C3’ of 
the ribose sugar unit of RNA, through the same pathway in reverse. Thus the mechanism of action 
involves a transphosphorilation reaction followed by an hydrolysis to form a 3' monophosphate 
nucleotide [126]. 
 
Figure 33 Schematic representation of RNase A catalytic mechanism 
 
The third active site residue, Lys41, also interacts with the phosphate group, stabilizes the trigonal 
bipyramidal intermediate and can potentially act as a general base in RNA cleavage.  
Thanks to crystallographic studies on RNases, especially bovine pancreatic ribonuclease, and their 
complexes with mononucleotides and oligonucleotides, other sites, apart from the active one, have 
been identified on RNases surface. These sites play a key role in determining activity and specificity of 
the enzyme [135]. Thus usually it is preferable to talk about RNases subsites [136-138]. In particular 
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these subsites are divided into P subsites, in which RNA phosphate groups are bound, and B subsite, 
which interact specifically with bases. Referring to RNase A numeration, P1 subsite, lined by catalytic 
residues His12, Lys41 and His119, binds the phosphate group to be hydrolyzed, whereas the P0 
(residue Lys66) and the P2 (Lys7 and Arg10) subsites bind the upstream and downstream phosphate 
groups, respectively. The pyrimidine specificity of enzymes results from the binding of the base in a 
narrow pocket on the surface of the enzyme, named B1, formed by Val43, Thr45, Phe120, and Ser123, 
whereas the downstream base is located in the less specific B2 subsite, constituted by the loop 65–72 
containing Asn71, Asn67 and Gln69. These sites, well defined in the case of RNase A, can be identified 
also in other members of the family [139, 140]. 
The RNase A superfamily has been known for a long time also as tetrapods RNases superfamily, 
because members have been found in amphibians, reptiles, birds and mammals [141]. Recently, a large 
number of sequences of fish DNAs and proteins has become available and it makes possible to 
recognize in fish proteins the unmistakable signature of an RNase sequence (CKXXNTF) [142, 143]. 
This has led to the proposal to rename the pancreatic-like superfamily more generally as the vertebrate 
RNase superfamily. 
Ribonucleases with special biological functions 
Many members of the vertebrate RNase superfamily are endowed with special biological functions, 
distinct from their catalytic action of degrading RNA, but strictly dependent on it. In particular these 
functions include angiogenic [144], antifertility [145], anti-pathogen [146], cytotoxic [147] and 
immunosuppressive [148] activities. 
Angiogenins 
Angiogenesis describes a process of endothelial cell stimulation to form new blood vessels and is 
critical for maintenance of tissues and support of growth. This process is essential for embryonic 
development, wound healing, proliferation of the endometrium and several other physiological 
processes [149], but plays an important role also in a variety of pathological conditions, such as diabetic 
retinopathy, psoriasis and neoplasia [150, 151]. Furthermore angiogenesis is crucial for tumour 
development, through the vascularisation of the tumor mass.  
The RNases with angiogenic activity, usually called angiogenins, form a distinct family within the 
superfamily, and were firstly identified for their ability to stimulate the growth of blood vessels [152] 
and then recognized as ribonucleases. With respect to the superfamily prototype, RNase A, they have a 
sequence homology of about 30% and only three disulphide bridges instead of four [153]. They lack the 
disulphide bond between Cys65 and Cys72, which has been found to be important in determining 
RNase A activity and stability [154]. Angiogenins are characterized by a very low ribonucleolitic activity 
(103-104 lower than RNase A one), which is essential for angiogenic activity and is probably caused by 
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the obstruction of pyrimidine binding subsite B1 by the side chain of a C-terminal residue (Gln117 in 
human angiogenin) [139]. Interestingly, it has been proved that an increasing of ribonucleolitic activity 
determines the lost of angiogenic function. However, it is not yet known how these proteins stimulate 
blood vessels growth, which are their physiological substrates and why angiogenic function is so strictly 
dependent on a low catalytic activity.  
Angiogenins from fishes 
Several fish RNases have been identified and studied in the last years: five recombinant RNases from 
the tropical bony fish zebrafish (Danio rerio)[142, 143, 155, 156], two from the atlantic salmon (Salmo 
salar) [157], two from the rainbow trout (Oncorhynchus mikiss) and ten from medaka (Oryzias latipes) [143]. 
These proteins share about 30% sequence homology with RNase A and about 35% with human 
angiogenin (hAng). Their RNA degrading activity is comparable to that of mammalian angiogenins and, 
as in the case of these latter enzymes, their angiogenic activity is strictly dependent on the integrity of 
the catalytic activity. On the other hand, all fish RNases studied so far have been found to be endowed 
with bactericidal activity. Surprisingly, this latter activity has been found to be maintained when the 
RNases are either catalytically inactivated or fully denatured. 
A phylogenetic analysis (Figure 34) indicates that fish RNases form two distinct, related clusters. One 
of them comprises the RNases from trout, salmon, and zebrafish, excluding ZF-RNase-4, the other, 
comprising zebrafish RNase 4 and some medaka RNases, includes also the amphibian RNases. It has 
been proposed that this indicates the presence of two distinct RNase genes in the last common 
ancestor of fish and amphibians. 
 
Figure 34 Rootless phylogenetic tree of the vertebrate RNase superfamily. Zebrafish and salmon RNases are 
marked in red  
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On the basis of the findings of angiogenic and antibacterial activities of zebrafish and salmon RNases, 
different hypotheses have been proposed on the physiological and evolutive significance of the early-
diverged fish RNases. The relationship of fish RNases to mammalian angiogenins prompts the 
hypothesis that the whole superfamily of vertebrate RNases evolved from early angiogenic RNases. In 
the course of evolution, RNases endowed with strong RNase activity were selected for, and used for 
digestive functions, or diverse non-catalytic bioactions. Separate clades of RNases instead, poorly active 
as RNA degrading enzymes, conserved the angiogenic activity, all through the divergence of mammals. 
On the contrary the finding that fish RNases have a strong bactericidal activity suggests that the 
ancestral RNases were more likely proteins engaged in host defence [158]. Further studies and a deeper 
characterization of fish ribonucleases may show that the two hypotheses are indeed only one: that the 
ancestral RNases were engaged both in angiogenic and host defence activities. 
A detailed analysis of structural and functional characteristics of these ancestral ribonucleases could 
provide the opportunity to study evolutionary forces at work on a conserved protein scaffold. 
Antitumor RNases 
As it happened in the case of angiogenins, also other proteins have been discovered thanks to their 
biological functions and then recognized as ribonucleases. This is the case of Onconase, a homolog of 
RNase A present in the oocytes and early embryos of Rana pipiens, which shows a high cytotoxic activity 
towards cancer cells and thus it has been early identified as a promising cancer chemotherapeutic agent 
[159-161]. Numerous cancer lines are sensitive to Onconase; their treatment with 10-100 nM enzyme 
leads to suppression of cell cycle progression, followed by apoptosis or cell senescence. Onconase has 
advanced to a phase IIIb confirmatory clinical trial for the treatment of unresectable malignant 
mesothelioma [162]. Other amphibian RNases exhibit a specific toxicity to cancer cells, such as 
ribonucleases extracted from Rana catesbaiana (RC-RNase) and Rana japonica (RJ-RNase) [163, 164]. All 
these enzymes are monomeric, share about 30% sequence homology with RNase A and present four 
disulphide bridges, three of which common to bovine pancreatic ribonuclease. Furthermore they have a 
particularly high thermal stability compared with other members of the family [161]. 
Among cytotoxic RNases peculiar is the case of bovine seminal ribonuclease, or BS-RNase, since it is 
the only natural dimeric protein of the superfamily. In particular BS-RNase is a homodimer that shares 
more than 80% amino acid homology with the family prototype RNase A. The dimeric structure is 
stabilized by two intermolecular disulphide bridges (between Cys31 of one chain and Cys32 of the 
other one). Moreover the enzyme exists as two conformational isoforms [165], one of which (MxM) 
presents the reciprocal exchange between the two chains of the N-terminal helix [166], a phenomenon 
absent in the other one (M=M) [167]. The special structural feature observed in MxM BS-RNase is 
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known as 3D domain swapping.  
Although the research concerning antitumor RNases is extremely rich, many aspects of their properties 
are still unclear. It is evident that their molecular target is RNA, but these proteins have distinct 
preference to cellular RNAs [168]. For example it has been demonstrated that Onconase in vivo acts on 
tRNA, but not on mRNA and rRNA [169-172], whereas BS-RNase preferentially hydrolyze ribosomial 
RNA [173]. These results are not valuable in vitro, where the enzymes cleave indistinguishably rRNA 
and mRNA. It has been suggested that the in vivo specificity may be caused by a different cellular 
localization, by protein modifications after internalization or by the different accessibility of RNA when 
complexed with cellular proteins [168]. The internalization is a crucial step for exploiting the antitumor 
activity, but it is not fully understood. RNases are basic proteins that well interact with the negative 
cellular membrane and it has been proved that an increasing of positive charge on the RNases surface 
rises their cytotoxic activity [174, 175]. Specific receptors have been identified on cellular membrane 
that bind RC-RNase and RJ-RNase [163], an Onconase receptor has been discovered only on glyoma9 
cells [176], whereas no cellular receptor for BS-RNase has been found [168]. Thus it has been proposed 
that RNases are internalized by endocytosis, and indeed they have been localized in endosoms [177-
179]. In contrast to Onconase, which enters the cytosol from the endosome recycling compartment, 
mammalian RNases are translocated into the cytosol from the endosomal/lysosomal pathway [177, 
179]. In the endosomes (as well as in the lysosomes) and in the cytosol the RNases have to resist the 
attack by proteases. Furthermore, to exploit their cytotoxic function, RNases have to avoid the binding 
by the proteic ribonuclease inhibitor (RI), which represents the 0.01-0.1% of the whole protein 
component of mammalian cells cytosol [180]. RI is a 50 kDa protein with the typical leucine rich fold, 
composed by 15 β-α motifs [181] arranged in a characteristic horseshoe shape [182].  
 
 
Figure 35 Cartoon representation of the proteic ribonuclease inhibitor, RI (coordinates derived from the structure 
of RI-RNase A complex, PDB code 1DFJ) 
  
RI contains many reduced cysteine residues, essential for its activity: when one single residues is 
oxidized all the others are quickly oxidized and RI loses its capability of binding and inhibiting RNases 
and is digested by cellular proteases [183]. The biological role of this protein is still unclear, probably it 
exerts a protective function to the cell against secreted ribonucleases. Furthermore it could also regulate 
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RNases biological activities [184].  
RI forms with RNase A a 1:1 complex, which is one of the strongest known proteic complex. It is 
characterized by a dissociation constant of 10-14 M [185] and by an incredible shape complementarity 
between the two components [186, 187]. Mammalian ribonuclease inhibitor is able to bind many 
RNases, such as angiogenins [188], but it does not recognize amphibian ribonucleases, which lack 
several aminoacid residues essential for the binding [189], and the dimeric BS-RNase, which is sterically 
inaccessible [187, 190], all proteins endowed with cytotoxic and antitumor activities. On the basis of 
these findings it has been proposed that monomeric RNases can be converted into antitumor agents if 
modified to evade the binding of RI [191]. 
BS-RNase  
As mentioned before, BS-RNase represents a unique case in the pancreatic ribonuclease superfamily 
because of its quaternary structure. It is a covalent homodimeric enzyme, isolated as an equilibrium 
mixture of swapped (MxM-BS) and unswapped (M=M-BS) forms, at 7:3 ratio [165]. The interchanging 
N-terminus (residues 1–15) is linked to the main body of the enzyme through the residues 16-22 [166]. 
This peptidic segment, which is called hinge peptide and is very important in determining the swapping 
phenomenon, adopts different conformations in the two isomers. In both isoforms, the two chains are 
linked by two antiparallel disulfide bridges, involving Cys31 and Cys32 (Figure 36), and the two Leu 
residues in position 28 form stabilizing hydrophobic interactions across the molecular twofold axis 
[166, 167].  
   
Figure 36 Cartoon representation of the BS-RNase isoforms, MxM on the left (PDB code 1BSR), M=M on the 
right (PDB code 1R3M). The two subunits are coloured red and green respectively, the hinge peptides are in blue, 
cysteines involved in interchain bridges are represented in ball and sticks 
 
Although the two dimers present an almost undistinguishable external shape, the cytotoxic action is a 
peculiar property of MxM-BS [192]. It is believed that this feature is linked to the fate of the enzyme in 
the cytosol. Due to the reducing property of this cellular compartment, M=M-BS dissociates into 
monomers (Figure 37 A), which are strongly inhibited by RI [193], whereas MxM-BS survives as a 
metastable non-covalent swapped dimer (NCD-BS), whose overall shape hinders the formation of the 
complex with RI [190]. Furthermore, in NCD-BS the cysteines are close to each other (Figure 37 B), 
and this feature may explain the higher stability of its disulfide bridges with respect to those of M=M. 
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Figure 37 Cartoon representation of the monomer (PDB code 1N1X), on the left, and of the non covalent dimeric 
form (NCD) (PDB code 1TQ9), on the right, of BS-RNase. In NCD-BS the two subunits are coloured red and 
green respectively, in both models cysteines involved in interchain bridges are represented in ball and sticks 
 
 
The 3D domain swapping, first observed in the case of MxM-BS-RNase in 1993, it has been found in 
the last years in an increasing number of proteins. It has been suggested that 3D domain swapping 
could play a role in important biological functions, such as up- and down-regulation of enzymatic 
activities [194], immunosuppressive and antitumoral properties [195, 196], regulation of molecular 
assembly [197, 198], structural organization of viruses [199]. It has been also proposed that it is a 
structural feature in the formation of amyloids fibers [200], which are associated with several 
degenerative diseases such as Alzheimer, type II diabetes, and many others[201]. It is a powerful 
process to create dimers, since the interactions that pre-exist within the monomer are re-used in the 
dimer (Closed-Interface) and at the same time novel chain-chain interactions are formed (Open-
interface) [197]. Therefore in the present context it represents a promising mechanism to transform 
non-cytotoxic monomeric ribonucleases into antitumor dimeric or oligomeric enzymes. Indeed many 
efforts have been devoted to deeply understand the phenomenon and to identify the structural 
requirements of the BS-RNase swapped structure. This especially because the seminal enzyme presents 
some risks as therapeutic due to its immunogenicity [202]. This problem could be overcome inducing 
antitumor activity in pancreatic ribonucleases, in particular in the bovine and human proteins [203]. 
Transforming these proteins in a NCD-BS-like dimeric form seemed to be an easy task, because of the 
high sequence homology (more than 80% in both cases). Through a minute analysis of MxM-BS crystal 
structure a few amino acid residues that are likely to play a crucial role in the swapping phenomenon 
and in the stabilization of the quaternary structure have been identified [166, 191, 204]. In particular the 
two cysteine residues in position 31 and 32, requested for the dimerization, the proline in position 19 
and the leucine in position 28. Pro19 determines a characteristic conformation of the hinge peptide and 
stabilizes the quaternary structure occupying a hydrophobic patch on the other subunit lined by 
residues Tyr25 and Gln101, whereas Leu28, as said before, stabilizes the dimer through symmetric 
hydrophobic interactions [166, 167, 190]. The importance of these two residues has been proved by the 
production and characterization of the BS-RNase double mutant, P19→A/L28→Q, with the two 
residues substituted by the corresponding RNase A ones. This mutant (PALQ) presents a reduced 
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antitumor activity with respect to the wild type enzyme, and its NCD form has an open structure that 
allows the binding of RI (Figure 38) [205].  
 
Figure 38 Cartoon representation of the putative complexes between RI and NCD-BS (A) and NCD-PALQ (B). 
RI is coloured blue, whereas the two subunits of NCD molecules are coloured red and green respectively 
 
Starting from these findings several human pancreatic RNase (HP-RNase) and RNase A mutants with 
different ability to evade RI and to exert cytotoxic activity have been obtained [191, 204, 206]. 
New strategies to obtain antitumor RNases: immuno-RNases 
A very promising strategy to obtain efficient and selective antitumor therapeutics is based on the use of 
antibodies, which specifically bind antigens on the external surface of sick cells [207]. During the past 
two decades, immunotoxins, made up of antibodies or miniantibodies (single chain variable fragment, 
scFv), fused to toxins, have been proposed as anticancer drugs [208]. These chimeric proteins combine 
the potent toxicity of toxins with the antigen specificity of antibodies. However, in many cases the 
murine nature of the immunomoieties, the plant or bacterial nature of the toxin moieties, and their high 
toxicity have greatly limited the therapeutic potential of these constructs [209]. A very recent strategy in 
anticancer immunotherapy is that based on immunoconjugates, in which an RNase substitutes for the 
toxin [210, 211]. Since mammalian RNases are not toxic to cells unless internalized, these fusion 
proteins are not immunotoxins but rather immunoprotoxins [212]. Furthermore antibodies can deliver 
a RNase into tumor cells leading to a high RNase concentration in the cytosol. In this way, although 
some enzymes are inhibited by RI, proteins able to exert their catalytic activity are still available in the 
cell, through a saturation effect [213]. 
Because of its preferential expression in tumor cells and its extracellular accessibility, an attractive target 
for immunotherapy is ErbB2, a trans-membrane tyrosine kinase receptor that is overexpressed on 
many carcinoma cells of different origin, and is associated with poor prognosis and with a more 
aggressive clinical behaviour [214, 215]. ErbB2 consists of a cytoplasmatic region, a trans-membrane 
tract and finally an extracellular domain (ECD) [216], in turn composed by four sub domain (I-IV) 
[217, 218].  
Part II - Introduction 
 
57 
 
 
Figure 39 Cartoon representation of the ErbB2 extra-cellular domain (ECD). The four domains are coloured 
green, cyan, purple and orange, respectively 
 
Several humanized immunoagents against the extracellular domain of ErbB2 have been produced and 
have been approved for clinical use or tests, such as Trastuzumab [219, 220] and Pertuzumab [221]. 
They are humanized antibodies of murine origin and present immunogenicity and cardiotoxicity as side 
effects. To overcome these problems the production of several human immunoagents against ErbB2 
has been attempted by prof. D’Alessio and his colleagues [212, 222-224]. In particular, they produced 
and characterized a human anti-ErbB2 scFv, named Erbicin [223], which in vitro is active against tumors 
that are resistant to other antibodies and both in vitro and in vivo is not cardiotoxic. This protein has 
been fused to HP- RNase to obtain an immuno-RNase, which retains the enzymatic activity of the 
wild-type enzyme and specifically binds to ErbB2-positive cells with the high affinity of the parental 
scFv [212]. It has been proved that immuno-RNase action is based on its RNase activity, exerted in the 
cytosol of internalized cells, reached directly from the endosomal compartment. After internalization by 
target cells, immuno-RNase becomes selectively cytotoxic in a dose-dependent manner at nanomolar 
concentrations [213]. Remarkably it does not present Trastuzumab drawbacks: it have no adverse 
effects on cardiac cells in vitro, it does not alter cardiac function in vivo, when tested on mice [225], and it 
is active on Trastuzumab resistant tumors. Is has been suggested that these immuno-RNase properties 
depend on a different binding on ECD, which in turn triggers a different signaling mechanism [213].  
Thesis purposes 
Concerning the ribonuclease system, the thesis purposes have been multiple.  
First of all, I focused my attention on the structural features of fish ribonucleases. During the first year 
of my PhD, the crystal structures of two zebrafish RNases, ZF-RNase-1 and -3, determined at alkaline 
pH, were published [155]; my work has thus been devoted to complete the structural characterization 
of ZF-RNases, through a combination of crystallographic analysis and computational techniques, 
principally homology modelling. The main purpose was to explain on molecular basis the different 
stability and activity properties of these highly homologues proteins. Furthermore, the study of a 
ribonucleases from Salmo salar (SS-RNase-2), a fish emerged about 70 million years before zebrafish 
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genome divergence, has been also attempted, because structural comparison among these fish enzymes 
could shed light on the evolution of the RNase scaffold from an ancestral protein.  
As a second point, domain swapped RNases endowed with cytotoxic activity, but characterized by a 
low immunogenicity, have been studied. Inspired by the dimeric nature of the cytotoxic BS-RNase, 
RNase A dimeric variants were designed to disturb the affinity of RI to the RNase A molecule. The 
structural determination at high resolution of the non covalent swapped dimeric forms (NCD) of 
RNase A mutants allowed to understand the molecular causes of the specific biological properties of 
these proteins and represents a crucial step toward the design of an RNase with low immunogenic 
response and improved antitumoral activity.  
Finally, this study has been focused on immunotoxins with specified cell-type cytotoxicity, constructed 
by fusing human pancreatic RNase to antibodies. In particular, a potent antitumor immuno-RNase was 
produced by combining HP-RNase with an human anti-ErbB2 scFv, Erbicin [212]. In order to define 
and implement the antitumor potential of immuno-RNase and to rationalize its properties with respect 
to other known anti-ErbB2 antibodies, the immuno-RNase epitope on ECD should be identified. The 
most straightforward method to characterize the intermolecular recognition is the structural 
determination of the complex using X-ray diffraction. However, when good quality crystals are not 
available, a powerful alternative is in silico analysis, based on homology modelling, rigid docking and 
molecular dynamic. Since the search for crystallization conditions was unsuccessful we decided to use a 
computational approach. To simplify the problem it was decided to first characterize the epitope that is 
recognized by the antibody. The results obtained will be used to clarify the role of ribonuclease in the 
immunoconjugate action. 
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RESULTS AND DISCUSSION 
Fish angiogenins 
In the last years RNases have been identified in genomes of several fishes: in particular five 
recombinant RNases from the tropical bony fish zebrafish (Danio rerio) [142, 143, 155, 156] and two 
from the atlantic salmon (Salmo salar) [157]. These proteins were expressed, purified and characterized 
by the group directed by prof. D’Alessio. They are endowed with bactericidal and angiogenic activities, 
the last function being strictly dependent on ribonucleolitic activity. Among zebrafish ribonuclease 
subfamily the sequence identity ranges from 26% to 73%. The enzymes present small differences in the 
thermodynamic properties, with ZF-RNase-2, -4 and -5 showing a slight higher stability with respect to 
ZF-RNase-1 and -3. A more variable catalytic activity is observed among ZF-RNases: a difference of 
three order of magnitude is found between the most active member, ZF-RNase-4, and the less active 
ones, ZF-RNase-1 and -2 [156]. Concerning salmon RNases, SS-RNase-1 is similar to zebrafish RNases 
for what concern the stability, whereas SS-RNase-2 is much more stable. The latter protein has also an 
elevated catalytic activity [157], comparable to that of ZF-RNase-5, but still lower than that of ZF-
RNase-4. A report of catalytic efficiency and melting temperature of ZF-RNases and SS-RNases 
compared to hAng and RNase A is presented in Table 8. 
 
Table 8 Catalytic efficiency and melting temperatures of ZF-RNases and SS-RNases compared to hAng and 
RNase A 
 
Enzyme Kcat/KM (M-1s-1) Tm (°C) 
ZF-RNase-1 5.3±0.39 x 102 54.9 
ZF-RNase-2 1.9±0.13 x 102 63.8 
ZF-RNase-3 2.2±0.15 x 103 55.5 
ZF-RNase-4 0.9±0.05 x 105 64.8 
ZF-RNase-5 1.2±0.09 x 104 64.3 
SS-RNase-1 2.3±0.22 x 102 62.4 
SS-RNase-2 7.0±0.69 x 104 71.1 
hAng 1.7±0.12 x 103 62.6 
RNase A 8.4±0.46 x 106 64.0 
 
ZF-RNase-5 
The search for crystallization conditions produced ZF-RNase-5 crystals which diffracted to 1.8 Å 
resolution.  
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Figure 40 Typical ZF-RNase-5 crystal 
 
The final protein model (residues 1-122), obtained by molecular replacement and refined to R 
factor=0.178 and Rfree=0.210, contains 969 protein atoms, 114 water molecules, 1 acetate and 2 
sulphate ions. A summary of the refinement statistics is presented in Table 9.  
 
Table 9 Refinement statistics for ZF-RNase-5 
 
Refinement Results  
Resolution limits (Å)  50.00-1.80 
Number of reflections used 
 in the refinement (F>2σ(F)) 
15282 
No. of reflections in working set 13762 
No. of reflections in test set 1520 
R/Rfree  0.178/0.210 
No. of protein atoms 969 
Ligand atoms and water molecules 127 
RMSD from ideal values  
Bond lengths (Å)  0.031 
Bond angles (°) 2.5 
Average B-factors (Å2)  
Protein, overall  24.96 
Main chains 23.61 
Side chains 26.30 
Solvent atoms 38.29 
Ion atoms 41.36 
Ramachandran plot statistics  
Residues in the most favored regions 
(%) 
95.0 
Residues in the additionally allowed  
regions (%) 
3.4 
Residues in the generously allowed  
regions (%) 
1.7 
 
ZF-RNase-5 is very similar to the other zebrafish RNases, whose crystal structures have been solved 
[155] (in comparison to ZF-RNase-1 and ZF-RNase-3 the RMSDs of the corresponding Cα atoms are 
0.70 Å and  0.91 Å respectively), whereas it is slightly different with respect to hAng [139] 
(RMSD=1.28 Å). 
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Figure 41 Cartoon representation of ZF-RNase-5 
 
Remarkably ZF-RNase-5 is the first structure of a zebrafish RNase that presents a sulphate ion in the 
P1 subsite; its interactions with the surrounding catalytic residues (His17, His117 and Lys45) and 
structured water molecules are similar to those found in RNase A [226] and other angiogenins [227, 
228]. The similarity of the active site architecture with that of RNase A extends to the subsite P2 
subsite, where Lys12 and Arg15 are the analogues of Lys7 and Arg10 in the bovine pancreatic enzyme. 
However, in ZF-RNase-5 the B1 subsite, delimited by Val47, Thr49, and Tyr118, is obstructed by that 
part of the C-terminal tail which is visible in the electron density map (residues 119-122). In particular, 
the side chain of Glu120 makes two hydrogen bonds with Thr49 and partly mimics the binding 
interactions of the pyrimidine base.  
 
Figure 42 Active site region of ZF-RNase-5. The structure of ZF-RNase-5 (green) is 
superimposed to that of RNase A (pink) in complex with the dATAA tetranucleotide (violet) 
 
In the present case, the orientation of the Glu side chain is enforced by the involvement of this residue 
in a pseudo type II’ β-bend, stabilized by a C10 hydrogen bond between the side chain of the preceding 
Asp119 and Gly121. 
In order to investigate whether the different behavior in the sulphate binding between ZF-RNase-5 and 
ZF-RNase-1 and -3 was not merely a result of differences in the environmental parameters used in the 
crystallization trials, structural analysis has been extended to crystals of ZF-RNase-1 grown at acidic pH 
and in the presence of an elevated concentration of SO4
2- ions. 
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ZF-RNase-1 
After an extensive screening of crystallization conditions, good quality crystals of ZF-RNase-1 were 
obtained at acid pH (ZF1_pH4.5), from a crystallization solution that contained 2.0 M ammonium 
sulphate and 0.1 M sodium acetate pH 4.5. These new crystals belong to the space group P212121, 
contain two molecules in the independent unit and diffract up to a resolution of 1.38 Å.  
 
 
Figure 43 Best crystals of ZF1_pH4.5 
 
The structure was solved by molecular replacement. The final model contains two protein molecules (A 
and B), very similar to each other (RMSD=0.42 Å when superimposing Cα atoms), 419 water 
molecules, 7 phosphate groups and 1 acetate one (Figure 44), and it has been refined to R-factor/Rfree 
values of 0.162/0.192.  
 
Figure 44 Cartoon representation of the two ZF-RNase-1 molecules in the asymmetric unit. The acetate ion and 
sulphate ions are shown as stick 
 
In order to investigate the dependence of the structural features of this protein on the pH, the structure 
at higher pH (7.3) was also solved (ZF1_pH7.3). It is very similar to ZF1_pH4.5: the Cα atomic 
positions for the two molecules in the asymmetric unit at the two pH do not differ significantly and 
their RMSD are in the range 0.14-0.47 Å. All non-glycine residues in the refined structures lie within 
"allowed" regions of the Ramachandran plot and the analysis of the electron density maps indicates that 
they are extremely well defined for both the protein chains at both pH. Detailed refinement statistics 
are reported in Table 10. The recombinant protein here analyzed lacks the first three residues in the 
sequence with respect to the crystal structure of ZF-RNase-1 at basic pH (ZF1_pH8, PDB code 2VQ8 
[155]). To simplify the comparison, the numbering of the latter is maintained in this work.  
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Table 10 Refinement statistics for ZF1_pH4.5 and ZF1_pH7.3 
 
 
ZF-RNase-1 
PH 4.5 
ZF-RNase-1 
PH 7.3 
Refinement Results   
Resolution limits (Å)  30.00-1.38 30.00-1.61 
Number of reflections used 
 in the refinement (F>2σ(F)) 
40180 27488 
No. of reflections in working set 36128 24765 
No. of reflections in test set 4052 2723 
R/Rfree  0.162/0.192 0.152/0.205 
No. of protein atoms 2075 2084 
Ligand atoms and water molecules 458 434 
RMSD from ideal values   
Bond lengths (Å)  0.027 0.028 
Bond angles (°) 2.4 2.4 
Average B-factors (Å2)   
Protein, overall  15.63 13.55 
Main chains 13.67 11.53 
Side chains 17.50 15.43 
Solvent atoms 36.06 30.42 
Ion atoms 33.06 36.15 
Ramachandran plot statistics   
Residues in the most favored 
regions (%) 
96.4 96.4 
Residues in the additionally 
allowed  regions (%) 
2.8 2.8 
Residues in the generously allowed  
regions (%) 
0.8 0.8 
 
The inspection of the electron density maps of ZF1_pH4.5 reveals that chain A binds five sulphate 
ions and chain B binds three sulphates ions and one acetate ion. Details of the interactions of these 
ions with the protein are reported in Table 11.  
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Table 11 Hydrogen bonds of sulphate and acetate ions in the structure of Zf1_pH4.5 
 
Chain A Chain B 
Sulphate  
Atom name  
(protein residue  
and residue number) 
Distance (Å) Sulphate and acetate 
Atom name  
(protein residue  
and residue number) 
Distance (Å) 
SO42- 3001   SO42- 3003   
O1 N (Tyr 107) 3.00 O1 N (Tyr 107) 2.85 
 NE (Arg 106) 3.02  NE (Arg 106) 2.98 
O2 NH2 (Arg 106) 3.17 O3 NE (Arg 106) 3.03 
    NH2 (Arg 106) 2.93 
SO42- 3002   CH3COO-    
O1 NH2 (Arg 25) 2.88 O NH2 (Arg 25) 2.89 
 NH2 (Arg 35) 3.05    
O2 N (Met 21) 3.20    
 N (Asp 20) 2.86    
 N (Pro 19) 3.16    
O4 NH1 (Arg 25) 3.18    
      
SO42- 3000   SO42- 3004   
O3 ND1 (His 119) 2.82 O4 NH2 (Arg 93) 2.23 
 NE2 (His 121) 2.53    
SO42- 3006   SO42- 3005   
O2 ND2 (Asn 73) 3.13 O3 NE (Arg 100 AC1) 2.59 
 NZ (Lys111 AC1) 2.85 O4 NH2 (Arg 100 AC1) 2.69 
   SO42- 3007   
   O4 N (Glu 114) 2.89 
 
The binding site of a sulphate (acetate in molecule B) and that of a second sulphate site are well 
conserved in both chains. The remaining non-equivalent sites are involved in packing contacts. The 
map of the anionic binding sites is strictly conserved in the structure at neutral pH, with the only 
exception of the acetate ion that is replaced by an additional sulphate anion. The surprising finding is 
that, in contrast to numerous crystallographic reports on RNase A [140, 226] and other members of the 
family [166, 229, 230], and angiogenins [227, 228], and despite the relatively high concentration in the 
crystallization mixture, none of the sulphate ions is located in the active site, as the anion binds 
preferentially to other regions of ZF-RNase-1, both at acid and neutral pH.  
The putative binding subsite B1 of the pyrimidine base is partially obstructed by the side chain of 
Glu122, located in the C-terminal segment of the protein. The position of this residue, fixed by two 
hydrogen bonds to Thr52, is common to all the angiogenins that have a Glu/Gln residue in the 
equivalent position, and to ZF1_pH8 [155]. 
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Figure 45 Omit Fo-Fc electron density map (5.0 σ level) of the obstructive Glu122 of ZF1_pH4.5 
 
Interestingly, the C-terminal segment, to which the obstructive glutamic residue belongs, is also the 
region where the largest differences are observed between the structure at basic pH [155] and those at 
lower pH. In ZF1_pH4.5 and ZF1_pH7.3, this region is better defined, probably due to packing 
interactions involving residues 125-127. In particular the acidic/neutral conformation is characterized 
by hydrophobic interactions between residues Val125, Val127, Pro48, Val49 and Val87 and by the 
formation of a hydrogen bond between N atom of Gly128 and O atom of Leu88. On the overall, the 
C-terminus causes an obstruction of B1 that is even greater than that produced in ZF1_pH8.  
Comparison among ZF-RNases, hAng and RNase A 
An extensive comparison among the known zebrafish RNases crystal structures (ZF-RNase-1, -3, -5) 
and homology models of the other two proteins (ZF-RNase-2 and -4) has been performed, with the 
aim to explain the different properties of these enzymes. Interestingly some general trends can be 
extracted from the structural features of the different members of the subfamily.   
Although the geometry of the P1 subsite is strictly conserved among ZF-RNases, it should be stressed 
that only ZF-RNase-5 binds a sulphate ion in this subsite. This result is enforced by the fact that ZF-
RNase-5 crystals were grown from solutions with a low ammonium sulphate concentration (0.2 M), as 
mentioned before. This feature is probably related to a cluster of positive charges (Arg9, Lys12 and 
Arg15) in the proximity of the ZF-RNase-5 active site. In particular, Lys12 and Arg15 correspond to 
Lys7 and Arg10 of RNase A, two residues which line the P2 subsite and are considered to be important 
for substrate binding [135]. An important role in determining the low catalytic activity of angiogenins in 
comparison to RNase A has been ascribed to the obstruction of the B1 subsite that occurs in most 
angiogenins [139, 227, 231]. In these molecules a Glu/Gln residue on the C-terminal tail protrudes in 
the B1 subsite and forms two hydrogen bonds with the threonine residue involved in the pyrimidine 
base recognition. This feature is also observed both in ZF-RNase-1 and ZF-RNase-5. In the latter, as 
for hAng, the Glu residue is involved in a pseudo type II’ β-bend, stabilized by a hydrogen bond 
between the amide nitrogen of Gly121 and the side chain of Asp119. This structural motif, which 
should further restrict the conformational space available to the glutamic residue, is not found in ZF-
RNase-1, where the Asp residue is replaced by a His. In this respect, it should be recalled that the 
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corresponding aspartate of RNase A (Asp121) forms a sort of “catalytic dyad” with His119 [232]. In 
the bovine pancreatic enzyme, the hydrogen bond between the side chains of these two residues 
stabilizes the histidine conformation that is supposed to be active during the transphosphorylation step. 
In ZF-RNase-5, just like in hAng, no interaction between the corresponding Asp and His is observed, 
and Asp is engaged in the two enzymes in interactions with Ser118 and Gly121, respectively (Figure 
46).  
 
Figure 46 Comparison between the C-terminal tails of ZF-RNase-5 (green) and RNase A (pink) 
 
However, it should be noted that a rotation of the Asp side chain from the t to g- conformation would 
bring the carboxylate group in a position to form the hydrogen bond with the catalytic histidine. 
Moreover, the rotation of the aspartic side chain also results in the disruption of the hydrogen bond 
with the second residue next along the chain (Gly121 in ZF-RNase-5). This would also destabilize the 
position of the C-terminal residue and favor the expulsion of Glu120 from the B1 subsite. This 
structural feature, together with the greater ability of ZF-RNase-5 to bind in the active site a sulphate 
anion, may account for the enhanced enzymatic activity of the latter with respect to ZF-RNase-1.  
It should be stressed that the most relevant differences between ZF-RNases and hAng are localized at 
the C-terminal tail. In hAng, this region adopts a well defined 310 helix conformation, which is anchored 
to the protein core by hydrophobic interactions involving residues downstream to the obstructive 
Gln117 (Ile119 and Phe120). In ZF-RNases the C-terminal segment seems to be much more mobile. 
Indeed, in ZF1_pH8 it is partially disordered and the segment visible in the electron density map 
assumes a different conformation when compared to that observed in the structures of ZF1_pH4.5 and 
ZF1_pH7.3 here reported. In ZF-RNase-5 the C-terminus appears even more disordered: the last 
visible residue in the electron density map is Gly121. This could be reflected in an increased capability 
of ZF-RNase-5 to adopt an alternative conformation of the C-terminal tail that allows the binding of 
substrate. Interestingly, despite ZF-RNase-2 shares a 73% of sequence identity with ZF-RNase-5, its 
catalytic activity is 100-fold lower. This result could be ascribed to a lower number of basic residues in 
the active site region of ZF-RNase-2 in comparison to ZF-RNase-5. Moreover, the putative B2 subsite 
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of the former enzyme appears to be less accessible, as a result of the presence of Arg107 replacing 
Gly109 in the latter (Figure 47).  
 
Figure 47 Homology model of ZF-RNase-2 with Arg107 represented as balls and sticks 
 
Concerning ZF-RNase-4, the most active member of the family of zebrafish RNases, its high activity 
could be due to the concomitant occurrence of an unobstructed B1 subsite, a feature also found in ZF-
RNase-3, and of a cluster of positive charges at the N-terminal helix, in particular the Lys9, just 
adjacent to catalytic His10 (Figure 48). In the neighborhood of the catalytic histidine (His10) this 
cluster could help substrate recognition.  
 
Figure 48 Homology model of ZF-RNase-4 with active site residues (Lys9, His10, Lys38, Thr42 and His106) 
represented as sticks 
 
From these observations what emerges is that, at least in the zebrafish subfamily, the B1 obstruction is 
not sufficient to justify the low ribonucleolitic activity of angiogenins; a key role is also played by 
electrostatic properties of P1 subsite. 
Furthermore, the structural differences noted among the different members of the zebrafish RNases 
subfamily, in particular at the C-terminal region, roughly correlate with their thermodynamic behavior. 
The presence of the pseudo type II’ β-bend at the C-terminal tail in ZF-RNase-2 and ZF-RNase-5, but 
not in ZF-RNase-3 and ZF-RNase-1, may be the source of their slightly different thermal stability. This 
feature is not present in the modeled structure of ZF-RNase-4, which also has a shorter N-terminal 
helix (Figure 48). Its stability, comparable to that of ZF-RNase-2 and ZF-RNase-5, may well be due to 
the compactness of the protein and in particular to the shorter length of the loop connecting helix II to 
the β-strand next in the sequence, a feature that the enzyme shares with hAng and RNase A.  
Finally, structural analysis highlights slight differences and common features in helix II of the zebrafish 
Part II – Results and discussion 
 
68 
 
proteins. In ZF-RNase-5 this helix, which encompasses residues 24-36, begins with a turn in a 310 
conformation and terminates with a turn in a π helix conformation, with main chain hydrogen bonds 
Met31-Ile36 and Ser32-Lys35 and Lys35 in the Lα conformation. In the corresponding helix of ZF-
RNase-1 (residues 23-37) the network of hydrogen bonds (Ile30-Ile37 and Gly31-Lys36) is spatially 
conserved, with Lys36 in the Lα conformation, while the intervening extra residues Pro32 and Asn33 
bulges out of the helix, forming a type I β-bend (Figure 49). 
 
Figure 49 Superimposition of the C-terminal region of helix II of ZF-RNase-5 (green) and ZF-RNase-1 (blue). In 
the latter, residues Pro32 and Asn33 bulge out of the helix 
 
It is remarkable that despite the presence of the two extra residues, the C-terminal region of helix II of 
ZF-RNase-1 adopts the same conformation found in many other vertebrate RNases, such as RNase A 
[233], BS-RNase [166], hAng [139] and ZF-RNase-5. Since ZF-RNase-1 is more ancient than other 
members of the subfamily it may be surmised that RNase sequence has evolved removing the two extra 
residues to optimize this peculiar conformation involving a residue in a unfavorable Lα conformation. 
SS-RNase-2 
An extensive investigation of protein crystal growth conditions produced crystals of SS-RNase-2 
diffracting at 1.89 Å resolution.  
 
Figure 50 Typical SS-RNase-2 crystals 
 
Crystals contain two molecules in the asymmetric unit, rather similar to each other: their Cα atoms 
overlay with an RMSD of 0.8 Å. The Ramachandran plot reveals that in the partially refined model 
91.8% of residues lies in the most favored regions and 6.6% in the other allowed regions with the 
remainder 1.6% in outlier regions.  
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Figure 51 Cartoon representation of the two SS-RNase-2 molecules in the asymmetric unit 
 
Globally SS-RNase-2 structure results very flexible: in both molecules no electron density is observed 
for the last two C-terminal residues and fragmental density is found corresponding to 113-117 segment, 
an important region to which a putative catalytic residue, His113, belongs. It should be underlined that 
thermal factors values for both molecules are quite high, also in usually rigid regions, such as helix II 
and helix III (Figure 52), or in correspondence to residues such as Gln12 and Lys40 of the active site.  
 
Figure 52 Sausage representation of the two SS-RNase-2 molecules in the asymmetric unit. The color and tube 
size are based on the B factor, where the color scale is from dark blue to red, with red corresponding to the 
highest B factor and dark blue to the lowest B factor. 
 
SS-RNase-2 globally adopts the typical RNase fold, with three α-helices and six β-strands and its 
structure is stabilized by three disulphide bridges, typical of angiogenins. Furthermore SS-RNase-2 
shares another common feature with angiogenins, the B1 subsite obstruction by the side chain of a C-
terminal residue [139, 155, 231], in this case Asp119. However slight differences are observed with 
respect to other RNases: SS-RNase-2 has a longer β2 and a shorter β5 strands and substantial 
dissimilarities are found in helix II. In SS-RNase-2 this region is longer and more regular than in the 
other proteins: it starts with a turn in 310 conformation, a conformational feature conserved in ZF-
RNase-1 and ZF-RNase-5 structures, but continues with an α-helix (residues 23-33), with the canonical 
i-i+4 hydrogen bonds pattern. As previously discussed, this helix in the other RNases encompasses 
only six residues, whereas the following four describe a π-helix, involving a residue with a unfavorable 
Lα conformation. On the contrary in SS-RNase-2 all the residues adopt allowed conformations. 
The most relevant and interesting structural features of SS-RNase-2 are localized at the C-terminal tail. 
A surprising finding is that segment 112-118 does not adopt a β-strand conformation, as happens in all 
the other RNases, but it is unstructured and very flexible, whereas the 118-124 segment, which adopts 
the expected β-strand conformation, is anchored to the protein main body thanks to interactions 
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between Asp119 and Thr44 (a residue analogue to RNase A Thr45). Furthermore this peptide fragment 
is also involved in intermolecular contacts between the two protein molecules in the asymmetric unit. 
The unusual conformation of the 112-118 fragment results in a collapsed P1 subsite: the side chain of 
His113 occupies the substrate binding site. However it should be stressed that electron density maps 
corresponding to this residue are not very clear. Activity tests have shown that this protein has a 
consistent ribonucleolitic activity [157], which seems in apparent contrast with the structural results. 
However, the high flexibility of SS-RNase-2 could facilitate a conformational variation of all the C-
terminal segment (residues 112-126) toward a well defined structure, with unobstructed subsites, which 
favours the substrates recognition.  
It should be also recalled that atlantic salmon lives at 10°C and therefore it is a cold adapted organism. 
Psycrophilic proteins have been evolved in order to exert an efficient catalytic activity also at low 
temperature. It has been demonstrated that cold adapted enzyme could achieve this result thanks to a 
higher flexibility of the whole structure [234] or of active site residues [235]. In this context, SS-RNase-
2 could represent an extreme case: its active site is so mobile that it is only partially structured.  
SS-RNase-2: a new tile in the RNase mosaic 
Sequence alignment of SS-RNase-2, zebrafish RNases, human angiogenin and RNase A indicates a 
variability of the C-terminal tail, as is evident in Figure 53.  
 
Figure 53 Sequence alignment among SS-RNase-2, zebrafish RNases of known structure, hAng and RNase A. 
Residues belonging to the C-terminal β-strand are coloured in red 
 
However sequence alignment does not correspond to the structural one. Structural analysis allows to 
cluster these enzymes into two groups: RNases with an obstructive C-terminal segment (hAng, ZF-
RNase-1 and -5), which have a shorter β-strand, and RNases with a free B1 subsite (RNase A and ZF-
RNase-3), which have a longer β-strand. Remarkably SS-RNase-2 does not correspond to either of 
these two groups: it has an obstructed B1 subsite, but its β-strand better aligns with that of RNases 
with a free B1 subsite. Thus a different alignment, based on structural features including the obstructive 
residue, could be proposed (Figure 54) 
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Figure 54 Structural alignment among SS-RNase-2, zebrafish RNases of known structure, hAng and RNase A. 
Residues belonging to the  C-terminal β-strand are coloured in red 
 
From this it emerges that in the salmon protein a three residue insertion is present downstream the 
putative catalytic histidines (His113), which could determine the greater mobility of the C-terminal tail 
observed in the crystal structure. Furthermore, it should be noted that, although in SS-RNase-2 the 
obstructive residue (Asp119) has a shorter side chain with respect to that of other angiogenins (Glu or 
Gln), it is still able to interact with Thr44, thanks to the peculiar structure of the C-terminal segment, 
discussed before.  
In the case of SS-RNases we thought better do not apply the homology modelling approach used to 
obtain the structures of ZF-RNase-2 and -4. The SS-RNase-2 model is so unusual and different from 
the other RNases that we preferred not use it for homology modelling of SS-RNase-1. In the future we 
will further search crystallization conditions for the latter protein, moreover we will try to obtained new 
crystal forms of SS-RNase-2, in order to confirm its peculiar structure.  
Non covalent swapped dimeric form of RNase A mutants 
Many efforts have been devoted in the last decades to convert monomeric non-cytotoxic RNases, 
which though present a low immunogenicity, such as human and bovine pancreatic RNases, into non-
covalent swapped dimeric forms, endowed with antitumor activity. The availability of a well known 
model, BS-RNase, has allowed the production, through a homology mutation approach, of several 
dimeric RNase A variants. In particular I focused my attention on three RNase A mutants produced by 
prof. Picone and her coworkers: LCC, with substitution Q28→L, K31→C, S32→C, PLCC, with the 
additional substitution A19→P, and GNPSCC, which embodies the whole sequence of the seminal 
enzyme hinge peptide plus the two cysteines (S16→G, T17→N, A19→P, A20→S, K31→C, S32→C). 
All these proteins do exhibit a cytotoxic activity, though at a much lower level than BS-RNase [191, 
204, 206, 236]. Structural determination by X-ray crystallography of their NCD forms provides a 
powerful tool to understand the molecular basis of the different biological activity of these proteins 
with respect to the model enzyme, BS-RNase, and to design new mutants with improved biological 
actions. And indeed, thanks to the results achieved, a new RNase A mutant has been proposed to prof. 
Picone during my PhD, namely GPLCC (PLCC with the additional substitution S16→G), which has 
been found to have an antitumor activity similar to that of the seminal enzyme. Thus NCD-GPLCC 
has been crystallized as well, and its structure determined from two different crystal forms.  
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NCD-PLCC, NCD-LCC, NCD-GNPSCC 
The non covalent dimeric form of the three RNase A mutants, LCC, PLCC and GNPSCC, were 
crystallized and diffraction data were collected in the range 1.60-1.99 Å. The structure of NCD-LCC 
was determined in the presence of the substrate deoxycytidylyl (3’,5’)-2’ -deoxyguanosine (dCpdG), and 
that of NCD-PLCC was obtained both in the ligand-free (lf) and in the dCpdG legated form (lb) 
(structural results obtained during the development of my graduated thesis). Matthews coefficients 
calculations show that in all the cases the asymmetric unit contains one dimer molecule and the 
inspection of the residual electron density maps corresponding to hinge peptide regions confirmed the 
somewhat expected result that the three dimers do swap their N-terminal α-helices (Figure 55). 
However, it should be underlined that in NCD-PLCC and in NCD-LCC, one of the two hinge peptides 
is disordered, electron density corresponding to residues 20-21 and 19-21 of the second chain of NCD-
LCC and NCD-PLCC respectively is missing. 
 
Figure 55 Cartoon representation of the overall structure of lf-NCD-PLCC. Alchilated cystein residues are also 
shown in ball and stick representation 
 
The basic structural units, formed by residues 23-124 of one chain and the swapped residues 1-15 of 
the partner chain, are very similar in the three dimers (RMSDs after superimposition of Cα atoms are in 
the range 0.5-0.6 Ǻ), and, for each dimer, are related by a local twofold symmetry, as observed for most 
of the NCD swapped dimers of RNases. In the refined structures all non-glycine residues, except Ser23 
in both forms of NCD-PLCC and in NCD-GNSPCC, lie within allowed regions of the Ramachandran 
plot. Detailed refinement statistics are reported in Table 12. 
  
Part II – Results and discussion 
 
73 
 
 
Table 12 Refinement statistics for the NCD forms of the three RNase A mutants, LCC, PLCC and GNSPCC 
 
 
Lb-NCD-LCC NCD-GNSPCC Lf-NCD-PLCC 
Lb-NCD-PLCC 
(previous results) 
Refinement Results     
Resolution limits (Å)  30.0-1.94 30.0-2.00 40.00-1.60 40.00-1.90 
Number of reflections used 
 in the refinement (F>2σ(F)) 
18262 14995 29314 18705 
No. of reflections in working set 16459 13467 26371 16879 
No. of reflections in test set 1803 1528 2943 1826 
R/Rfree  0.181/0.227 0.188/0.246 0.172/0.217 0.175/0.223 
No. of protein atoms 1915 1915 1931 1893 
Ligand atoms 20 0 23 50 
Water molecules 233 123 397 210 
RMSD from ideal values     
Bond lengths (Å)  0.021 0.021 0.029 0.028 
Bond angles (°) 2.04 2.01 2.34 2.29 
Average B-factors (Å2)     
Protein, overall  22.24 25.83 27.80 22.26 
Main chains 21.01 25.00 26.28 21.06 
Side chains 23.52 26.72 29.37 23.52 
Solvent atoms 31.03 30.88 42.92 32.32 
Ligand atoms 40.04 - 30.93 47.44 
Ramachandran plot statistics     
Residues in the most favored  
regions (%) 
97.0 96.6 97.0 96.5 
Residues in the additionally allowed  
regions (%) 
3.0 3.0 2.6 3.5 
Residues in the generously allowed  
regions (%) 
- 0.4 0.4 - 
 
 
Diversified features are observed at the active site region of the dimers, in terms of ligands and their 
location. It should be stressed that the active sites are composite, as they are lined by residues of 
different chains. At one active site of lf- and lb- NCD-PLCC, a well-defined electron density clearly 
reproduces a trehalose molecule (Figure 56), a compound used for the cryo-stabilization of the crystals. 
The sugar is hydrogen bonded to Thr45, Lys66 and Asp121 and two water molecules, which, in turn, 
are linked to Asp83 and Ser123. The binding of trehalose does not affect significantly the active site. 
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Figure 56 Omit Fo-Fc electron density map (3.8σ level) at the active site region of the first structural unit of NCD-
PLCC  
 
In the ligand-free form, water molecules are located in the active site (Figure 57 A) similarly to other 
RNases [194, 226, 230, 233], whereas in lb-NCD-PLCC, dCpdG is positioned in the retrobinding 
mode, similar to that observed for guanine containing dinucleotide complexed to RNase A [140, 237, 
238] and BS-RNase [194]. The purine base is located in B1 subsite and is hydrogen bonded to Thr45, 
the guanine ribose moiety is exposed to the solvent and does not interact with the protein and the 
phosphate group is only partially visible (Figure 57 B). 
A   B  
Figure 57 A) Omit Fo-Fc electron density map (3.0 σ level) at the active site region of the second structural unit of 
lf-NCD-PLCC. Catalytic residue His119 adopts two different conformations. B) Omit Fo-Fc electron density map 
(3.5 σ level) at the active site region of the second structural unit of lb-NCD-PLCC. 
 
Differences in the active site organization between the two structural units are also apparent for lb-
NCD-LCC. Water molecules are located in one site, whereas at the second site the dinucleotide binds 
in the productive mode (Figure 58), with the pirimidine base in B1 and the phosphate in P1. The ribose 
and the downstream guanine base are not visible, as found also in the productive binding of UpG to 
RNase A [140].  
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Figure 58 Omit Fo-Fc electron density map (3.5 σ level) at the active site region of the second structural unit of lb-
NCD-LCC  
 
In contrast with the first two variants, the active sites of lf-NCD-GNPSCC present a very similar 
organization: well-defined water molecules occupy the B1 and P1 subsites at positions similar to those 
found for the ligand-free structures of other pancreatic-like RNases [140, 226, 230, 233]. 
Dimers structures have been compared to each other and with the model protein NCD-BS [190]. In 
particular the subunit assembly between two dimers can be monitored by the value of the angle ψ 
needed to superimpose the second structural unit after the superposition of the first one. NCD-LCC 
and NCD-GNPSCC are very similar to each other (ψ=4°), whereas PLCC is slightly different (ψ≈30° 
with respect to the other two dimers). Remarkably a particularly high ψ value is obtained when the three 
dimeric mutants are compared with the closed quaternary structure of NCD-BS (ψ≈105°). It should be 
stressed that in NCD-BS interface between subunits (Open interface) is formed by the two hinge 
peptides (residues 16-22) and by two helices II (residues 23-34), which comprise the S-
carboxyamidomethyl-cysteines and the two Leu28 [190]; on the contrary in the three structures here 
reported, the helices 23-34 are far away from each other and the corresponding residues 28 are fully 
exposed to the solvent, despite the fact that this position is occupied by a Leu in LCC and PLCC 
(Figure 59).  
 
Figure 59 Cartoon representation of the overall structure of lf-NCD-PLCC. Leu28 of 
the two subunits are also shown in ball and stick representation 
 
This structural results provide an explanation for cytotoxic assays performed on these proteins. The 
insertion of the two Cys residues, Pro19 and Leu28 is not sufficient to induce the RNase A dimeric 
variants to adopt the quaternary structure of NCD-BS. In the open quaternary structure of these 
mutants one subunit can be easily modeled into RI horseshoe cavity without steric interference 
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produced by the partner chain (Figure 60), as previously shown for other open dimers [205] as well as 
for the more compact ND-RNase A molecule [190].  
 
Figure 60 Cartoon representation of the putative complex between NCD-GNSPCC (green and magenta) and RI 
(blue) 
 
The finding that NCD-PLCC adopts a quaternary structure completely different with respect to NCD-
BS has been somewhat surprising, since it was predicted that the insertion of Pro19 and Leu28 in the 
RNase A sequence would strongly push the quaternary organization toward that observed for NCD-
BS. However, interesting novel features emerges from a comparison of the hinge peptide structures of 
various dimers. For the present compounds, the electron density in this region reveals significant 
differences. In lf-NCD-GNPSCC both hinge peptides are well ordered and adopt two different 
conformations starting from Ser20. In one chain, residues 21-24 and 22-25 form two nested type IV β-
turns, whereas in the second chain, a type I β-turn is formed by residues 18-21. For the structures of 
NCD-PLCC and NCD-LCC one of the two hinge peptides is disordered, whereas the second one can 
be fully traced in a well defined electron density map. The ordered conformation in the two structures 
is similar (RMSD=0.37 Å), irrespective of the presence of a proline residue in PLCC, and is 
characterized by a type I β-turn encompassing residues 18-21, followed by a 310 helix (residues 22-24).  
When comparing hinge peptides with those of other swapped dimers of RNases remarkable results are 
obtained. In Figure 61 the hinge peptides are shown together with those of various swapped dimers of 
RNases: the overlay of the peptides was obtained by imposing for all dimers a common orientation of 
the partner chain.  
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Figure 61 Superimposition of the hinge peptide regions of lf-NCD-PLCC, lb-NCD-LCC, lf-NCD-GNPSCC, 
NCD-BS (PDB code 1TQ9 [190]), PM8 (PDB code 1H8X [239]) and NCD-PALQ (PDB code 3BCP [205]). For 
sake of clarity, the side chains of some residues have been omitted 
 
As it clearly emerges from Figure 61, the observed conformations cluster in two broad families, which 
part at the level of residue 16, according to whether this residue is Gly (G-conformation) or Ser (S-
conformation). In the first case (G-conformation), the stretch 16-19 is tightly bound on the surface of 
the partner chain and, in particular, has the pirrolydine ring of Pro19 in the pocket formed by the side 
chains of Tyr25 and Gln101 of the other subunit (Figure 62).  
 
Figure 62 Van der Waals representation of the proline pocket: Pro19 side chain (green) is inserted into a cavity of 
the partner subunit lined by Tyr25 and Gln101 
 
Interestingly, in all cases, the conformation of Gly16 falls in a region of the Ramachandran map 
forbidden for a non-Gly residue. When Pro is replaced by an Ala (as in NCD-PALQ [205]), this residue 
is shifted away from the proline pocket. On the other hand, when Gly is replaced by Ser, there is a 
dramatic modification of the hinge structure at the level of Ser16, which favours more opened and 
flexible conformations of the whole peptide, irrespective of the presence of proline in position 19 (S-
conformation in Figure 61). In one subunit of NCD-LCC and NCD-PLCC, residues 20-21 and 19-21, 
respectively, cannot be traced in the electron density maps. However, residues 16-18 adopt a structure 
that is very close to the S-conformation. 
Thus the analysis of the conformational preferences of the hinge peptide clearly suggests a strong 
synergic effect of the residues in the 16 and 19 position of the hinge peptide sequence. In order the 
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proline side chain be located in the proline pocket built on the surface of the partner chain, the residue in 
position 16 must assume a conformation not allowed for a non-glycine residue. With Pro19 firmly 
bound in the pocket, residues 16-19 stick on the protein surface and the flexibility of the hinge peptide 
is limited to the conformational variability of the segment 20-22. This significantly reduces the 
quaternary space accessible to the dimer and, in the presence of a Leu residue in position 28, should 
favor the acquisition of a compact structure similar to that of NCD-BS. 
NCD-GPLCC 
Moving on from structural results obtained for the three RNase A mutants, the new mutant GPLCC-
RNase A (with substitution S16G, A19P, Q28L, R31C and S32C) has been produced and tested for 
cytotoxic activity by prof. Picone group. The obtained results are particularly encouraging: GPLCC 
exerts a cytotoxic activity on SVT2 cells comparable to that of seminal enzyme (Figure 63).  
 
Figure 63 Cytotoxicity of BS-RNase and GPLCC on SVT2 cells  
 
In order to verify whether the biological properties of the new mutant depend on a quaternary structure 
of the NCD form similar to NCD-BS, the crystallization of NCD-GPLCC was attempted.  
Good quality crystals were obtained from a solution containing 30% PEG 20000 and 0.2 M ammonium 
sulphate at protein concentration 10 mg/ml and in presence of 7.4 mM dCpdG (lb-NCD-GPLCC) or 
7.4 mM dATAA (lf-NCD-GPLCC). Diffraction data were collected for both crystals at 2.61 Ǻ and 1.60 
Ǻ. Matthews coefficients calculations show that in both the cases asymmetric unit contains one dimer 
molecule, a clear solution was obtained by molecular replacement performed with AMoRe [118] and 
finally the inspection of the residual electron density maps corresponding to hinge peptide regions 
confirmed the expected result that the dimer swaps its N-terminal α-helices in both the crystal forms, 
although one of the two hinge peptides is disordered in the structure at 2.61 Å resolution. Furthermore, 
electron density analysis show that both active sites of the structure at 1.60 Å resolution bind a sulphate 
ion and a dCpdG molecule in retrobinding mode [140] (lb-NCD-GPLCC), but no electron density 
corresponding to the tetranucleotide dATAA is observed in the active sites of the other structure (lf-
NCD-GPLCC). 
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Lb-NCD-GPLCC structure has been completely refined to R/Rfree values of 0.179/0.228 respectively, 
whereas refinement of lf-NCD-GPLCC is in progress. Refinement statistics for the first model are 
reported in Table 13.  
. 
 
Table 13 Refinement statistics for lb-NCD-GPLCC 
 
Refinement Results  
Resolution limits (Å)  50.00-1.60 
Number of reflections used 
 in the refinement (F>2σ(F)) 
27792 
No. of reflections in working set 25014 
No. of reflections in test set 2778 
R/Rfree  0.179/0.228 
No. of protein atoms 1949 
Ligand atoms and water molecules 283 
RMSD from ideal values  
Bond lengths (Å)  0.026 
Bond angles (°) 2.14 
Average B-factors (Å2)  
Protein, overall  24.50 
Main chains 23.44 
Side chains 25.60 
Solvent atoms 39.19 
Ligand atoms 31.43 
Ramachandran plot statistics  
Residues in the most favored regions 
(%) 
94.9 
Residues in the additionally allowed  
regions (%) 
4.7 
Residues in the generously allowed  
regions (%) 
0.4 
 
The surprising result is that quaternary structures of the dimer in the two crystal forms are completely 
different to each other (the value of the angle ψ needed to superimpose the second structural unit of 
the two dimers, after the superposition of the first one, is 88°).  
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A   B  
Figure 64 Cartoon representation of lb-NCD-GPLCC (A) and lf-NCD-GPLCC (B). In each structure the two 
subunits are coloured green and magenta, respectively 
 
Lb-NCD-GPLCC adopts an open quaternary structure, whose subunits are related by a 165° rotation 
around a pseudo symmetry rotation axis (Figure 64 A), very similar to the NCD forms of the other 
mutants analyzed before (the value of the angle ψ needed to superimpose the second structural unit of 
lb-NCD-GPLCC and NCD-LCC, NCD-PLCC and NDC-GNPSCC, after the superposition of the 
first one, is 3° in the three cases). On the contrary lf-NCD-GPLCC is more compact (Figure 64 B) 
(although it lacks one of the hinge peptides its buried surface area is 1780 Ǻ2 versus the 1460 Ǻ2 of lb-
NCD-GPLCC). It is characterized by a non-crystallographic twofold symmetry and a tight Open 
interface, mainly composed of residue 48-50 and 78-80 from the two subunits. However its assembly is 
different with respect to other closed non covalent dimers, especially with respect to NCD-BS [190] 
(ψ=144°) and ND-RNase A (PDB code 1A2W [240]) (ψ=156°).  
A deeper analysis of lf-NCD-GPLCC was performed to rationalize its open structure. The two hinge 
peptides are clearly defined in electron density maps and they adopt two different conformations. The 
first one is characterized by two nested β-turns, a type IV encompassing residues 21-24 and a type I 
encompassing residues 22-25. In the second one residues 18-21 are involved in a type IV β-turn and 
residues 21-24 in a type I β-turn. A comparison with the two hinge peptide conformations (G- or S-
conformation) described above shows that in NCD-GPLCC the first hinge peptide adopts a G-
conformation and the other one an S-conformation. In particular in lb-NCD-GPLCC the first one has 
a structure identical to that of NCD-BS for residues 15-19 (Figure 65 A) and, as expected, the Pro19 
occupies the proline pocket on the other subunit. However marked differences are observed for residue 
20-23 with respect to NCD-BS. This diversity could be ascribed to the presence of a sulphate ion in the 
present structure, which interacts with N atoms of Ser22 and Asn24 (Figure 65 B), and, directly or by 
water mediated contacts, with side chains of residue Ser21, Ser22, Ser23 and Asn24.  
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A   B  
Figure 65 A) Superimposition of the hinge peptide regions of lb-NCD-GPLCC (orange), lf-NCD-GPLCC (cyan) 
and NCD-BS (blue). For sake of clarity, the side chains of some residues have been omitted. B) Interactions 
between a sulphate ion and one of the hinge peptides of lb-NCD-GPLCC 
 
Thus it can be suggested that sulphate binding strongly affects hinge peptide conformation. As 
mentioned before the second hinge peptide adopts the S-conformation, with a solvent exposed Pro19, 
but its structure is different with respect to that observed in NCD-PLCC and NCD-LCC. Hinge 
peptides affect each other and this could determine the specific conformation found in NCD-GPLCC: 
the sulphate binding prevents the first hinge peptide to adopt a BS-like structure, in turn it pushes the 
other hinge peptide towards a different conformation and altogether this results in a open quaternary 
structure. Thus the observed dimer assembly could be influenced by crystallization conditions. 
Concerning lf-NCD-GPLCC, at a first glance (it should be recalled that we are talking of a preliminary 
model and not of a fully refined structure) the only visible hinge peptide adopts the expected G-
conformation. 
Both the NCD-GPLCC structures, even the most compact one, are still compatible with RI binding, in 
apparent contrast with its observed cytotoxic activity. However the high variability of quaternary 
structure found for this dimer should be stressed. This feature has been amply discussed for swapped 
dimers: they do not need to conserve interface interactions in order to preserve a dimeric structure, 
thanks to the presence of the swapping phenomenon. This results in a marked variability of the relative 
arrangement of the subunits within the dimers. Nevertheless, the case of NCD-GPLCC seems to be 
peculiar. The two quaternary assemblies are obtained from identical crystallization conditions, the only 
observed difference being the presence of the substrate analogue. This does not happen for other 
RNase dimeric mutants, such as PLCC, whose NCD structure is the same irrespective to substrate 
binding. 
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Immuno-RNase: ErbB2 epitope identification using a computational approach 
One of the most promising strategy in anticancer therapy is that based on immuno-conjugates in which 
an RNase is fused to an antibody or scFv specific for tumor cell. In this context prof. D’Alessio, prof. 
De Lorenzo and their co-workers have produced an immuno-RNase [212], composed of human 
pancreatic RNase and Erbicin, a human scFv direct against ErbB2 [223]. Both Erbicin and immuno-
RNase are selectively cytotoxic for ErbB2-positive cancer cells in vitro and in vivo and remarkably do not 
show cardiotoxicity, the most negative side effect of Trastuzumab, the only humanized anti-ErbB2 
antibody used in the therapy of breast carcinoma. Furthermore they act also on Trastuzumab resistant 
tumors. These attractive properties of Erbicin and immuno-RNase are likely due to a different ErbB2 
epitope recognized by Erbicin with respect to Trastuzumab. The structural characterization of the 
antibody-antigen complexes is required to obtain several insights into the molecular mechanism of 
action. In the present case, it has not been possible to perform crystallization experiments for these 
complexes, because the procedure of expression and purification of ECD has not yet been optimized 
by the group of prof. De Lorenzo. On the contrary, a careful search for crystallization conditions of 
Erbicin and immuno-RNase has been carried out without, unfortunately, a positive outcome. It seems 
clear that the modular structure of these immuno-agents induces a wide conformational variability that 
could interfere with the crystallization process. Thus, in order to identify the epitope and to 
characterize the immuno-RNase-ECD interactions, a computational approach has been employed. It 
should be underlined that HP-RNase and Erbicin are linked together through a 11 residues peptide, 
whose sequence is AAASGGPEGGS. The linker is long and flexible enough to assure that the two 
molecules can be considered separately. Thus, for simplicity, the analysis has been carried out on the 
antibody moiety of the fusion protein.  
To perform the calculation a three-dimensional model of Erbicin was built, using the canonical 
structures method for the hypervariable loops [241, 242] and standard homology modelling techniques 
for the framework regions. The model has a Prosa Z-score of -6.53, a value in the range of scores 
typically found in proteins of similar sequence length, and shows the 96.4% of residues in most 
favoured or in allowed regions of the Ramachandran map. The modelled protein  
(Figure 66) is characterized by a predominantly canonical structure with the peculiar feature of a short 
H3 CDR loop. Complementarity determining regions (CDR) are the antibody regions where the 
molecule complements an antigen's conformation, they determine the molecule specificity. Therefore, 
this Erbicin structural feature is particularly important to determine its properties with respect to other 
antibodies, as will be discussed below. 
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Figure 66 Cartoon representation of Erbicin. The H3 CDR loop is coloured red 
 
The model was used to identify the structural origins of the different binding properties between 
Erbicin and the two immuno-agents of known structures, Trastuzumab and Pertuzumab. The crystal 
structures of ECD in complex with the two humanized antibodies are known (PDB codes 1N8Z  and 
1S78 for complexes with Trastuzumab [218] and Pertuzumab [243], respectively), thus putative 
complexes between Erbicin and ECD were obtained aligning Erbicin to Trastuzumab (RMSD after Cα 
superimposition is 0.94 Å ) in the first complex (trastuzumab-like) and to Pertuzumab in the second 
complex (pertuzumab-like) (RMSD after Cα superimposition is 1.00 Å).  
Interactions between Trastuzumab and ECD are localized in ECD domain IV and mainly involve the 
antibody H3 CDR loop [218]. A similar binding mode is not allowed to Erbicin because, as mentioned 
before, it has an unusually short H3 loop (6 vs 11 residues) (Figure 67).  
  
Figure 67 On the left, trastuzumab-like putative complex of Erbicin (cyan) with ECD (orange). The structure of 
Trastuzumab (red) has been also reported for comparison. On the right a zoom on the interface region 
 
For what concern Pertuzumab, significant differences are found in primary structures of the two 
molecules. A few amino acid substitution (Asp31 with Ser31, Asn52 with Tyr52 and Asn54 with Gly54) 
in Erbicin prevents a pertuzumab-like binding. Asp31 of Pertuzumab forms a strong hydrogen bond 
with the side chain of Ser288 of ECD and participates to hydrophobic interactions with the C atoms of 
Val286 and Thr290 of ECD. Furthermore, ND2 atom of Asn52 forms a hydrogen bond with the 
backbone oxygen of Val286 of ECD, whereas OD1 and ND2 atoms of Asn54 interact with ECD 
backbone atoms belonging to Cys246 and Val286 and with side chain atoms of Thr268 [243]. In the 
putative pertuzumab-like complex these interactions are missing due to the presence of a serine instead 
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of Asp31 and a glicine instead of Asn54. An even more dramatic effect can be related to Erbicin Tyr52: 
the phenol ring is spatially too close to the backbone atoms of ECD Val286, thus the binding could be 
prevented due to an hindrance effect (Figure 68). 
   
Figure 68 On the left, pertuzumab-like putative complex of Erbicin (cyan) with ECD (orange). The structure of 
Pertuzumab (pink) has been also reported for comparison. On the right a zoom on the interface region 
 
In order to reveal the region of ECD involved in the interaction with Erbicin, a computational docking 
was performed by FTDock program. First of all the program performance was checked verifying if it 
was able to predict the ECD-Trastuzumab and ECD-Pertuzumab complexes. Then the calculations 
were carried on using the model of Erbicin, here reported. The solutions were evaluated with respect to 
several experimental and theoretical criterions. In particular, the model should have a high surface 
complementarity at the interface and should bury a surface area > 600 Å2 per molecule, it should have 
low energy and should be reproduced when docking calculations were repeated using different 
programs and/or input parameters. Upon clustering the 30 solutions with the lowest energy values, 
three potential models were identified and visually examined (Figure 69). 
     
Figure 69 Cartoon representation of the potential Erbicin-ECD models (model 1-3, from the left to the right). 
Erbicin is coloured cyan, ECD orange. 
 
Among the three solutions, model 1 fulfils the previous criteria. Indeed a total of 23 residues forms the 
interface, which is characterized by a good surface complementarity (Sc 0.55) and by an extensive 
buried surface area (about 750 Å2) over a long groove. In this model Erbicin binds ECD in the cleft 
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between the light and the heavy chain variable domains. As expected CDR loops are mainly involved in 
antigen recognition. The antibody peptide regions participating in direct contacts with ECD include the 
CDR H3 loop (Arg100, Asp101, Ser 102), the CDR H1 loop (Thr30, Ser31, Tyr32) and residues 
Tyr181, Ser182, Gly225, Ser226, Pro227. On the other side, the ErbB2 residues at the interface 
primarily involve a cysteine rich fragment, corresponding to region 162-190. In particular, Erbicin 
tightly binds the ECD fragment 167SRACHPCSPMCKGS180, in which Cys173 forms a disulfide bridge 
with Cys182 and Cys177 forms a disulfide bridge with Cys190. These findings well agree with the 
experimental evidences obtained by prof. D’Alessio and prof. De Lorenzo, which have shown that the 
epitope involves ECD residues 122-195, on domain I of ECD. A deep analysis of the model shows that 
a central role in the ECD-Erbicin interaction is played by His171 of ECD. This residue fills a 
hydrophobic cavity on Erbicin surface, lined by the side chains of tyrosines 223, 163, 164 and 181 and 
by Ser182 (Figure 70), where it may be involved in stacking interactions with one of the aromatic 
residues and in a hydrogen bond with the OG of the serine.  
 
Figure 70 A zoom on the Erbicin-ECD interface 
 
The results obtained by computational docking were validated by fluorescence studies. A peptide with 
the aminoacid sequence of ECD 167-180, and cysteines substituted by serines (SRASHPSSPMSKGS), 
was synthesized. Furthermore the peptide with the substitution His171→Glu was also produced, with 
the aim to investigate the role of His171. The fluorescence emission of Erbicin alone and in presence 
of each of the two peptides was monitored. A variation of the signal intensity is observed when the first 
peptide is added to Erbicin, whereas no marked difference with respect to Erbicin alone exists in 
spectra registered in presence of the mutant peptide. Finally the two peptides were used for 
competition ELISA assays with Erbicin and ECD by prof. De Lorenzo group. In according to 
predictions based on the docking model and to fluorescence results, it is found out that the not-
mutated peptide inhibits binding between the two molecules, whereas the other one exerts no 
inhibitory activity. 
To further refine the structure of the ECD-Erbicin complex, four 10ns MD trajectories were 
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performed using the coordinates of the rigid-docking obtained model as starting structure. Each of the 
produced trajectories represents a distinct exploration of the phase space accessible from the common 
starting structure. The generated structures are possibly representative of actual conformations of 
ECD-Erbicin complex in solution.  
The time evolutions of the secondary structure elements and of the total number of hydrogen bonds 
indicate that the two molecules maintain their correct globular folding in all the simulations. Similar 
results are obtained analyzing the root mean square deviations of the coordinates during the simulation, 
which indicate that the complex structure is quite stable in three trajectories and diverges in the last 2 ns 
of the last one.  
With the aim to characterize the relative orientation of the two molecules in the complex during the 
simulations, an average structure from the equilibrated portion of the four trajectories was calculated. 
The resulting structure is characterized by a slight larger buried surface area with respect to the starting 
model (790 Å2 versus 750 Å2). Although interface between Erbicin and ECD remains essentially the 
same, the antibody performs a rigid body accommodation with respect to the receptor (Figure 71). In 
this new model, Erbicin shows a translation of 3.8 Å of its centre of mass and a shift of the principal 
axis of inertia of the molecule of about 14° with respect to its initial position. The RMSDs per residue 
show that largest deviations are mainly localized at the ECD molecule, whereas very small deviations 
(RMSDs less than 3 Å) are detected for almost all the Erbicin structure. Notably, the largest deviations 
are far away from the receptor-ligand interface, thus confirming the reliability of the overall structure of 
the docked model. 
 
Figure 71 Comparison between the starting model of the ECD-Erbicin complex, as obtained from rigid docking 
(coloured blue) and the average model from MD simulations (Erbicin coloured cyan, ECD orange)  
 
Analysis of hydrogen bonds lifetime reveals that only two among the five hydrogen bonds that 
characterize the starting structure are well conserved (>50% lifetime) during the simulations. However, 
it is worth noting that new additional hydrogen bonds are observed. In particular, rather stable 
hydrogen bonds are formed between Asp143 and Cys170 of ECD and Arg100 of Erbicin (Figure 72), 
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between Ala169 of ECD and Gly225 of Erbicin and between His171 of ECD and Arg100 of the 
antibody.  
 
Figure 72 Hydrogen bond interactions between Erbicin Arg100 (cyan) and ECD Asp143 (orange) 
 
These results confirm the role of ECD residues Ala169, Cys170 and His171, three residues already 
identified as important for the ECD-Erbicin recognition from the analysis of rigid docking complex. 
Furthermore these data point up that an important role in the ECD-Erbicin recognition should be 
played by Erbicin Arg100, placed in the H3 loop.  
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MATERIAL AND METHODS 
 
Samples preparation 
Fish angiogenins 
All the fish angiogenins, ZF-RNase-1-5 and SS-RNase-1-2, were cloned, expressed and purified by 
prof. D’Alessio group, as previously reported [142, 143, 156, 157]. The proteins were provided as 
lyophilized samples from water unbuffered solutions. Several buffers were tested in order to identify 
the conditions ensuring the correct protein folding and the minimal interference with crystallization 
screening. All the lyophilized proteins were dissolved in 20 mM Tris/HCl buffer, pH 7.8. The accurate 
protein concentration was determined spectrophotometrically for all the ribonucleases, measuring their 
absorption at 280 nm. A small aliquot from each sample was used for circular dichroism analysis to 
check the conformational homogeneity before crystallization trials. CD spectra of fish angiogenins are 
typical of proteins with a α/β structure: they present a deep minimum at 208 nm, a shoulder at about 
220 nm and a high positive peak at 194 nm. As example in Figure 73 CD spectrum of ZF-RNase-5 is 
reported. 
 
Figure 73 CD spectrum of ZF-RNase-5 
Non covalent swapped dimeric form of RNase A mutants 
The four RNase A mutants, LCC, PLCC, GNPSCC and GPLCC, were cloned, expressed and purified 
in the monomeric form, with Cys31 and Cys32 linked to two glutathione molecules, by prof. Picone 
and her group, as described elsewhere [191, 244]. These protecting moieties were removed by mild 
reduction and the resulting free monomers readily formed swapped and unswapped dimers. The non-
covalent dimers were obtained from the equilibrium mixture (MxM and M=M) through selective 
reduction of interchain disulfide bridges, followed by alkylation of free thiol groups and by separation 
of monomeric and dimeric species by using gel permeation chromatography. All the samples were 
stored in 25 mM phosphate buffer at pH 6.7, because phosphate groups is known to stabilize non 
covalent swapped dimers by mimicking substrate phosphodiesteric group. This because the NCD form 
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contains two composite active sites with catalytic residues belonging to the different chains. In a few 
cases complexes between the ribonucleases and the substrate analog 2'-deoxycytidylyl(3',5')-2'-
deoxyguanosine (dCpdG) were prepared, by adding to the protein solution a 1:10 molar excess of the 
dinucleotide. 
Crystallization 
Fish angiogenins 
Initial crystallization trials for all the fish ribonucleases, ZF-RNase-1-5 and SS-RNase-1-2, were 
performed at 20°C using the sparse-matrix sampling method. The screening was carried out using 
commercially available kits (Crystal Screen kits I and II and Index kit from Hampton Research) and 
performing the trials both by hand and by a Nanodispersion Robotic System, “Microlab Starlet Nanojet 
8+1” by Hamilton Life Science Robotics, at the Istituto di Biostrutture e Bioimmagini of CNR. Promising 
conditions were identified for ZF-RNase-1, -3, -5 and SS-RNase-2. After optimization process, well 
diffracting crystals of ZF-RNase1 and -5 and SS-RNase-2 were grown. 
Crystals of all the three proteins were obtained by hanging drop vapour diffusion method at 20°C. In 
the case of ZF-RNase-1 the drops were prepared by mixing equal volumes of protein solution (15 
mg/ml) and reservoir solution containing 1.8-2 M ammonium sulphate and 0.1 M sodium acetate pH 
4.2-4.8 (ZF1_pH4.5). ZF-RNase-1 crystals were particularly big and resistant. Thus to analyze the 
structure of this enzyme at higher pH, the crystals, grown at pH 4.5, were transferred to harvesting 
solutions (2.3 M ammonium sulphate) buffered at pH values in the range 4.5-7.3. A stepwise procedure 
in which the pH was adjusted in steps of 0.2 was necessary to avoid deterioration of crystal quality. 
Crystals were stored under the final pH condition (ZF1_pH7.3) for a week with daily changes of the 
mother liquor. The best crystals of ZF-RNase-5 were obtained by mixing equal volumes of protein (15 
mg/ml) and precipitant solution containing 32 % w/v MPEG 2000, 0.1 M sodium acetate (pH 4.5) and 
0.2 M ammonium sulphate. Finally the best crystals of SS-RNase-2 grew at 15 mg/ml protein 
concentration from a solution containing 32 % w/v PEG 4000, 0.1 M Tris/HCl pH 7.4, 0.2 M sodium 
acetate and 1% v/v acetonytril at a protein-to-reservoir solution ratio of 1:1 in 1 µl drops. 
Preparation and crystallization of fish angiogenins in complex with substrate analogues 
With the aim to investigate the angiogenins/oligonucleotide interactions, many attempts to obtain the 
complexes were done. Because it was found that thermal unfolding of RNases, including fish RNases, 
is a reversible process, we tried to facilitate the substrate analogues binding by heating solutions of the 
proteins in presence of an excess of oligonucleotide at 40°C or 60°C, two temperatures corresponding 
to starting and ending points of the unfolding process, respectively, for ten minutes. Then the samples 
were slowly cooled down to room temperature and left one night at 20°C. The correct refolding of the 
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RNases was monitored by circular dichroism measurements. It was found that a small aliquot of the 
sample precipitates, but the supernatant is perfectly folded. Thus the samples were used for 
crystallization trials. Good quality crystals were obtained in the case of ZF-RNase-1 and ZF-RNase-3 in 
presence of dCpdG or 3’UMP, and in the case of SS-RNase-2 in presence of 3’UMP or of the tetra 
deoxynucleotide dACAA. Unfortunately diffraction data analysis showed that in none of these cases 
the substrate analogue binds the angiogenin.  
Non covalent swapped dimeric form of RNase A mutants 
Crystals of all the NCD mutants were obtained by hanging drop vapour diffusion method at 20°C 
using a protein concentration of 10 mg/ml. NCD-GNPSCC and NCD-PLCC were crystallized in a 
ligand free form, lf-NCD-GNPSCC and lf-NCD-PLCC (the NCD-PLCC-dCpdG complex structure, 
lb-NCD-PLCC, was previously solved during the degree thesis), NCD-LCC was crystallized in complex 
with the dinucleotide, lb-NCD-LCC, whereas NCD-GPLCC in both the forms (lf- and lb-NCD-
GPLCC). Crystallization conditions are reported in Table 14.  
 
Table 14 Crystallization conditions for NCD forms of RNase A mutants 
 
Lb-NCD-LCC Lf-NCD-PLCC Lf-NCD-GNPSCC Lb-/ lf-NCD-GPLCC 
21% w/v PEG 35000, 
0.2 M sodium acetate, 
0.1 M Tris/HCl H 8.5 
26% w/v PEG 4000, 
0.2 M ammonium sulphate, 
0.1 M Tris/HCl H 8.5 
30% w/v PEG 4000, 
0.2 M lithium sulphate, 
0.1 M Tris/HCl H 8.5 
30% w/v PEG 20000, 
0.2 M ammonium sulphate 
7.4 mM dCpdG - - 7.4 mM dCpdG/7.4 mM dATAA 
 
Data collection 
Diffraction data from all the NCD-RNase A mutants, with the exception of lf-NCD-PLCC and lf-
NCD-GPLCC, and from all the fish angiogenins were collected in-house on a Saturn944 CCD 
detector. The X-ray radiation used was Cu Kα radiation from a Rigaku Micromax 007 HF generator. 
Diffraction data from lf-NCD-PLCC and lf-NCD-GPLCC and from one crystal of ZF1_pH4.5 were 
collected by using synchrotron light at ELETTRA, Trieste. All crystals were flash-cooled at 100K in 
supercooled N2 gas produced by an Oxford Cryosystem and maintained at 100K during the data 
collection. Crystals were flash-cooled after the addition of 25% v/v glycerol to the harvesting solution. 
All the data were indexed, processed and scaled with HKL2000 program [115]. Detailed statistics on 
data collection are reported in Table 15 and Table 16. Matthews coefficient calculation suggested the 
presence of one dimer in the asymmetric unit of all the NCD-mutants crystals, one protein molecule in 
the asymmetric unit of ZF-RNase-5 crystals and two protein molecules in the asymmetric unit of ZF-
RNase-1 and SS-RNase-2. 
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Table 15 X-ray data collection statistics for fish angiogenins 
 
 
Rmerge = ∑hkl∑i |Ii(hkl)-<Ii(hkl)>|/ ∑hkl∑i Ii(hkl), where Ii(hkl) is ith intensity measurement of the reflection hkl, including symmetry related reflections, and 
<Ii(hkl)> is its average.  
Values in brackets are for the highest resolution shell
  
 
ZF-1_pH4.5 
(low resolution) 
ZF-1_pH4.5 
(high resolution) 
ZF-1_pH7.3 ZF-RNase-5 SS-RNase-2 
Space group P212121 P212121 P212121 I4132 P21 
Unit-cell parameters      
a (Å) 41.43 41.34 41.57 126.49 28.97 
b (Å) 49.01 48.97 49.18 126.49 70.75 
c (Å) 110.05 109.91 110.28 126.49 53.54 
α (°) 90.00 90.00 90.00  90.000 90.00 
β (°) 90.00 90.00 90.00  90.000 90.92 
γ (°) 90.00 90.00 90.00  90.000 90.00 
Resolution limits (Å) 
30.00-1.65 
(1.71-1.65) 
30.00-1.38 
(1.42-1.38) 
30.00-1.61 
(1.67-1.61) 
50.00-1.80 
(1.86-1.80) 
50 - 1.89 
(1.96 - 1.89) 
No. of observations 746245 430152 451397 913538  
No. of unique reflections 27166 41877 28093 16327 17350 
Completeness (%) 97.8 (81.9) 89.7 (54.1) 93.3 (51.4) 99.9 (99.9) 99.4 (96.3) 
I/σ(I) 21 (3) 29 (2) 24 (5) 24 (3) 15 (2) 
Average multiplicity 7.1 3.2 4.9 10.0 3 
Rmerge (%) 5.9 (23.8) 4.9 (38.5) 5.4 (11.5) 9.5 (64.8) 7.2 (31) 
Mosaicity 0.48 0.43 0.65 0.52  
VM (Å3Da-1) 1.95 1.94 1.97 2.92 1.97 
Solvent content (%) 37.0 36.7 37.54 57.90 37.67 
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Table 16 X-ray data collection statistics for non covalent swapped dimeric form of RNase A mutants 
 
 
Rmerge = ∑hkl∑i |Ii(hkl)-<Ii(hkl)>|/ ∑hkl∑i Ii(hkl), where Ii(hkl) is ith intensity measurement of the reflection hkl, including symmetry related reflections, and 
<Ii(hkl)> is its average.  
Values in brackets are for the highest resolution shell
 lb-NCD-LCC lf-NCD-PLCC lf-NCD-GNPSCC lf-NCD-GPLCC lb-NCD-GPLCC 
Space group P21 P21 P21 P21 P21 
Unit-cell parameters      
a (Å) 37.09 37.67 38.14 46.76 37.39 
b (Å) 62.35 64.68 57.46 55.90 59.10 
c (Å) 56.64 55.12 58.50 46.72 56.51 
α (°) 90.00 90.00 90.00 90.00 90.00 
β (°) 93.6 97.2 90.2 106.18 91.98 
γ (°) 90.00 90.00 90.00 90.00 90.00 
Resolution limits (Å) 
30.00-1.94 
(2.01-1.94) 
50.00-1.60 
(1.66-1.60) 
50.00-1.99 
(2.06-1.99) 
50.00-2.61 
(2.70-2.61) 
50.00-1.60 
(1.66-1.60) 
No. of observations 252202 875737 505371 63530 650134 
No. of unique reflections 19072 33531 15901 6945 29332 
Completeness (%) 99.5 (95.5) 97.0 (93.8) 90.7 (56.5) 96.7 (74.5) 89.8 (74.8) 
I/σ(I) 19 (7) 18 (3) 21 (5) 11.9 (4.4) 13.3 (2.8) 
Average multiplicity 3 7 6 3.7  3.8 
Rmerge (%) 4.9 (14.3) 7.0 (37.0) 8.0 (28.5) 12.2 (24.6)  8.4 (48.7) 
Mosaicity 0.8 0.8 0.9 0.60 0.64 
VM (Å3Da-1) 2.41 2.38 2.29 2.10 2.23 
Solvent content (%) 48.98 48.30 46.27 41.29 44.81 
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Structure determination and refinement 
All the structures, solved by molecular replacement, were refined with CNS program [119]. At the end 
of the refinement the geometry of all the refined protein structures were monitored using 
PROCHECK [116] and WHATCHECK [117] programs. 
Fish angiogenins 
The structure of Zf1_pH4.5 was solved by molecular replacement, using the program Phaser [120] and 
the model of the homologous bovine angiogenin (PDB code 1AGI) [231], from whom loop regions 
and peptide segments with very different amino acid sequence were removed, as the structure of the 
protein determined at pH 8.0 (Zf1_pH8) was not yet available. Molecular replacement was carried out 
using lower resolution data at 1.65 Å whereas higher resolution data (1.38 Å), collected later, were used 
for refinement. A clear solution was obtained with a Z-score of 5.3 and an LLG of 43.  
Phaser [120] program was also employed to solve the structure of ZF-RNase-5 using Zf1_pH4.5 as 
starting model, whereas the structure of SS-RNase-2 was solved using the program AMoRe [118] and 
Zf1_pH4.5 as search model (the correlation for the highest solution was 67.2, with an R factor of 33.0).  
Missing peptide segments were rebuilt, when possible, using the program arp/warp of the CCP4 
package [124] and by manual interventions using the program O [110] and Fourier difference maps 
calculated with CNS [119]. Each refinement step was followed by manual interventions using the 
program O to correct minor errors in the positions of some side chains and to identify solvent and ion 
sites. At the end of the refinement process, after inclusion of low resolution data and bulk solvent 
correction, good values of the crystallographic factors R and Rfree were obtained (see Table 9 and Table 
10). 
Non covalent swapped dimeric form of RNase A mutants 
All the structures were solved by the molecular replacement method, using the program AMoRe [118] 
and a search model formed by the region 1-14 and 25-124 of the RNase A structure (PDB code 1KF3) 
[233]. In all the cases the cross-rotation function, calculated using data in the 10–3.5 Å resolution range, 
clearly showed two prominent peaks, which were ascribed to the two protein chains. Then the 
translation function was calculated and the solution with the highest correlation and lowest R factor 
was fixed. A new translation function search, performed on the remaining rotation solutions, allowed to 
find the peaks corresponding to the second subunits. Eventually, by visual inspection of solutions with 
the program O, it was possible to build all the dimers, whose subunits correspond to the first molecular 
replacement solution and to a molecule that is symmetry related to the second solution. Hinge peptides 
were rebuilt manually, when possible, visualizing Fourier difference maps with the program O. The 
structures were refined using a similar protocol: each refinement run performed with the CNS program 
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was followed by manual interventions using the program O to correct minor errors in the positions of 
some side chains. Visual inspections were also performed to identify water molecule sites and to locate 
the ligand molecules. At the end of the refinement process, after inclusion of low resolution data and 
bulk solvent correction, the crystallographic factors R and Rfree reached values indicating good quality 
structures ( see Table 12 and Table 13). The partially refined structure of lf-GPLCC, in the 10.0-2.61 Å 
resolution range, has a R factor of 0.23 and a Rfree of 0.32 . 
Homology modelling 
Fish angiogenins 
Since no crystal was obtained for ZF-RNase-2 and ZF-RNase-4, the structures of these enzymes were 
determined in silico by homology modelling. In particular they were modelled with the SWISS-MODEL 
server [245], using as reference the crystal structure of ZF-RNase-5 and ZF-RNase-3 [155], 
respectively. The templates were chosen on the basis of the highest score and the lowest E-value found 
with a BLAST search against the PDB database. Positional sequence identity between ZF-RNase-2 and 
ZF-RNase-5 is 73%, whereas that between ZF-RNase-4 and ZF-RNase-3 is 33%. The models 
produced by the server were then manually adjusted to built missing residues on the N-terminal α-
helical region and energy-minimized in vacuo by means of the GROMOS96 force-field, following a 
procedure previously reported [246, 247]. 
Immuno-RNase 
Also in the case of the immuno-RNase the extensive and detailed research of the crystallization 
conditions did not produce positive results. It was, therefore, decided to obtain a model of the 
antibody, Erbicin, by homology modelling. Erbicin structure was built by using the canonical structures 
method for the hypervariable loops [241, 242, 248] and standard homology modelling techniques for 
the framework regions. Briefly, the framework structure of the light and heavy chain variable domains 
(VL and VH) from the PDB code 1DZB [249] was used as the scaffolding on which the six 
complementarity determining regions (CDR) loops are built. The CDR loops were assigned according 
to the definitions proposed by Chothia and coworkers [241, 242] with the exception of the H3 CDR 
loop that is predicted de novo. This is a short (6 residues) loop, which should have a reduced 
conformational accessible space and only few conformations compatible with the rest of the protein 
structure. The Erbicin model was validated by the PROCHECK [116] program ProsaII [250] and 
CCP4 [124] programs.  
Rigid docking and molecular dynamics 
Rigid docking [251] of the Erbicin model onto ErbB2 ECD was performed using FTDock [252]. Given 
two molecules, FTDock computes the three-dimensional transformations of one of the molecules with 
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respect to the other with the goal of maximizing surface shape complementarity while minimizing the 
number of steric clashes. The scoring method of FTDock also includes electrostatic filters. The 
candidate models were then scored according to an energy function. The solutions were visually 
examined, clusterized and evaluated with respect to experimental and theoretical criterions. The final 
complex structure was then studied to analyze the intermolecular contacts and identify specific residue 
interactions between the proteins. This protocol allowed a successful prediction of the structure of 
ECD-Pertuzumab (PDB code:1S78 [243]) and ECD-Trastuzumab (PDB code 1N8Z [218]) complexes. 
A protein-protein interaction server was used to identify the residues at the interface in the complex 
and to evaluate the interface features. The presence of putative hydrogen bonds and salt bridges were 
calculated with HBPLUS program [121]. Assessment of the complex model using the PROCHECK 
[116], ProsaII [250] and CCP4 [124] programs suggests that it has a low energy, a good stereochemical 
quality, and structural features of the interface (including the surface complementarity Sc value 
comparable with those observed in ECD-Tratuzumab and ECD-Pertuzumab complexes. 
The model obtained by the rigid docking calculation was further refined using molecular dynamics 
(MD) techniques. MD simulations were performed with the GROMACS 3.2 package [253] using a 
procedure described elsewhere [229, 254, 255]. Briefly, four distinct simulations of 10ns, differing in 
initial velocity coupled to protein atoms, were performed at a constant temperature of 300K, using 
periodic boundary conditions. In all cases a non bonded cut-off of 14 Å for the Lennard Jones 
potential and a dielectric constant of 1 were used. The treatment of coulombic interactions was carried 
out by using the Part Mesh Ewald method (PME) [256], with a grid size of 0.9 Å. All bond lengths 
were constrained by Lincs [257]. The Newton’s equation was integrated within a time step of 2 fs and 
atomic coordinates were saved for analyses every 0.5 ps.  
 
The figures were generated using Pymol (http://pymol.org) and Molscript [258]. 
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APPENDIX: SIDE PROJECTS 
 
 
During the PhD work, I have also been involved in the structural analysis, performed by X-ray 
diffraction and spectroscopic techniques, of superoxide dismutases (SODs) extracted from bacteria: 
PhSOD, from the psycrophilic eubacterium Pseudoalteromonas haloplanktis, and SmSOD, from Streptococcus 
mutans.  
The characterization of PhSOD falls in the more general study of psycrophilic proteins, voted to 
understand the molecular basis of cold-adaptation. The structures of this protein from two different 
crystal forms and of its complex with sodium azide, that inhibits the enzyme catalysis, were delucidated 
at a resolution in the range 2.10-1.50 Å. The crystallographic information was combined with a 
characterization of the chemical and thermal stability, performed by circular dichroism and 
fluorescence measurements, of both PhSOD and its mesophilic counterpart from Escherichia coli, 
EcSOD. The extensive comparison of structural and biophysical data, in particular of the 
conformational flexibility that was obtained by analysis of crystallographic B factors, for PhSOD and 
EcSOD leads to remarkable results. These dimeric enzymes share a large structural similarity, such as a 
conserved tertiary structure and arrangement of the two monomers, an almost identical total number of 
inter- and intra-molecular hydrogen bonds and salt bridges. However, the cold-adapted PhSOD shows 
an increased flexibility of the active site residues with respect to its mesophilic homologue. The 
denaturing temperature of PhSOD is comparable with that of EcSOD, on the contrary, the values of 
the denaturant (urea and guanidinium chloride) concentration at the transition midpoint, lower for 
PhSOD with respect to EcSOD, are in line with the psychrophilic/mesophilic origin of the proteins. 
Altogether, these data provide additional support to the hypothesis that cold-adapted enzymes achieve 
efficient catalysis at low temperature by increasing the flexibility of their active site; moreover, our 
results underline how fine structural modifications can alter enzyme flexibility and/or stability without 
compromising the overall structure of a typical rigid enzyme, such as SODs.  
Two PhSOD mutants, with a fully exposed free cysteine (Cys57) mutated either to Arg (C57R) or to Ser 
(C57S), were also characterized by X-ray diffraction and biophysical techniques. The structure of C57R 
was determined from two different crystal forms at 2.06 and 1.66 Å, respectively, whereas that of C57S 
was solved at 1.97 Å. The X-ray structures of the mutants show that the introduction of the arginine 
allows the formation of additional salt bridges on the protein surface, whereas the Cys→Ser 
substitution leaves the protein structure essentially unaltered. In agreement with crystallographic results, 
thermal and denaturant induced unfolding followed by circular dichroism and fluorescence reveals that 
the mutant C57R significantly alters the protein thermal and denaturant resistance, whereas the C57S 
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mutant does not. These findings are useful to understand the role of electrostatic interactions in the 
unusual thermal tolerance of this psychrophilic enzyme: they support the conclusion that the thermal 
resistance of PhSOD strongly depends on the distribution of charged atoms on the surface. 
The case of SmSOD is particularly interesting because it is a cambialistic enzyme. Unlike most metal-
enzymes, it is able to bind and/or exchange two different metals, Mn or Fe, in its active site. The 
specific activity, as well as the sensitivity to inhibitors, depends on the metal nature. Temperature and 
guanidinium chloride induced unfolding was investigated by means of circular dichroism, fourth 
derivative UV spectroscopy and fluorescence measurements. Our data show that both unfolding 
processes occur through a three-state model, characterized by functional dimeric intermediates species, 
with different three dimensional structures. It is interesting that SmSOD is the smallest dimeric protein, 
known so far, that populates dimeric rather than monomeric intermediates during denaturation 
processes. Very recently diffracting crystals of SmSOD have been obtained and the structure at 2.15 Å 
resolution is under refinement. The comparison of SmSOD structure with those of other Fe-SOD and 
Mn-SOD, will help in the identification of the molecular bases of the enzyme ability to bind either Fe 
and Mn.  
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 A. Merlino, I. Russo Krauss, I. Castellano, E. De Vendittis, A. Vergara, F. Sica 
Crystallization and preliminary X-ray diffraction studies of a psychrophilic iron superoxide dismutase 
from Pseudoalteromonas haloplanktis 
Protein & Peptide Letters, 15 (4): 415-418 (2008) 
Abstract 
The Antarctic eubacterium Pseudoalteromonas haloplanktis (Ph) produces a cold-active iron superoxide 
dismutase (SOD). PhSOD is a homodimeric enzyme, that displays a high catalytic activity even at low 
temperature. Using hanging-drop vapour-diffusion technique, PhSOD has been successfully crystallized 
in two different crystal forms. Both crystal forms are monoclinic with space group P21 and diffract to 
2.1 Å resolution. Form I has unit-cell parameters a=45.49Å b=103.63Å c=50.37Å β=108.2° and 
contains a homodimer in the asymmetric unit. Form II has unit-cell parameters a=50.48Å b=103.78Å 
c=90.25Å β=103.8° and an asymmetric unit containing two PhSOD homodimers. Structure 
determination has been achieved using molecular replacement. The crystallographic study of this cold-
adapted enzyme could contribute to the understanding of the molecular mechanisms of cold-adaptation 
and of the high catalytic efficiency at low temperature. 
 
 
 A. Merlino, I. Russo Krauss, M. Perillo, C.A. Mattia, C. Ercole, D. Picone, A. Vergara, F. Sica 
Towards an antitumor form of bovine pancreatic ribonuclease: the crystal structure of three non-
covalent dimeric mutants 
Biopolymers 91(12): 1029-37 (2009)  
Abstract 
The cytotoxic action of bovine seminal ribonuclease (BS-RNase) depends on its non-covalent swapped 
dimeric form (NCD-BS), which presents a compact structure that allows the molecule to escape 
ribonuclease inhibitor (RI). A key role in the acquisition of this structure has been attributed to the 
concomitant presence of a proline in position 19 and a leucine in position 28. The introduction of 
Leu28, Cys31 and Cys32 and, in addition, of Pro19 in the sequence of bovine pancreatic ribonuclease 
(RNase A) has produced two dimeric variants LCC and PLCC, which do exhibit a cytotoxic activity, 
though at a much lower level than BS-RNase. The crystal structure analysis of the non-covalent 
swapped form (NCD) of LCC and PLCC, complexed with the substrate analogue 2’-
deoxycytidylyl(3’,5’)-2’-deoxyguanosine, has revealed that, differently from NCD-BS, the dimers adopt 
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an opened quaternary structure, with the two Leu residues fully exposed to the solvent, that does not 
hinder the binding of RI. Similar results have been obtained for a third mutant of the pancreatic 
enzyme, engineered with the hinge peptide sequence of the seminal enzyme (residues 16-22) and the 
two cysteines in position 31 and 32, but lacking the hydrophobic Leu residue in position 28. The 
comparison of these three structures with those previously reported for other ribonuclease swapped 
dimers strongly suggests that, in addition to Pro19 and Leu28, the presence of a glycine at the N-
terminal end of the hinge peptide is also important to push the swapped form of RNase A dimer into 
the compact quaternary organization observed for NCD-BS.  
 
 
 I. Russo Krauss, A. Merlino, A. Randazzo, L. Mazzarella, F. Sica 
Crystallization and preliminary X-ray analysis of the complex of human alpha-thrombin with a 
modified thrombin binding aptamer 
Acta Crystallogr Sect F Struct Biol Cryst Commun. 66(Pt 8): 961-3 (2010) 
Abstract 
The thrombin-binding aptamer (TBA) is a consensus DNA 15-mer that binds specifically to human α-
thrombin at nanomolar concentrations and inhibits its procoagulant functions. Recently, a modified 
TBA (mTBA) containing a 5’–5’ inversion-of-polarity site has been shown to be more stable and to 
possess a higher thrombin affinity than its unmodified counterpart. The structure of the thrombin–
TBA complex has previously been determined at low resolution, but did not provide a detailed picture 
of the aptamer conformation or of the protein–DNA assembly, while that of the complex with mTBA 
is unknown. Crystallographic analysis of the thrombin–mTBA complex has been attempted. The 
crystals diffracted to 2.15 Å resolution and belonged to space group I222. 
 
 
 A. Merlino, I. Russo Krauss, I. Castellano, E. De Vendittis, B. Rossi, M. Conte, A. Vergara, F. 
Sica 
Structure and flexibility in cold-adapted iron superoxide dismutases: the case of the enzyme isolated 
from Pseudoalteromonas haloplanktis  
Journal of Structural Biology 172: 343-352 (2010) 
Abstract 
Superoxide dismutases (SODs) are metalloenzymes catalysing the dismutation of superoxide anion 
radicals into molecular oxygen and hydrogen peroxide. Here, we present the crystal structure of a cold-
adapted Fe-SOD from the Antarctic eubacterium Pseudoalteromonas haloplanktis (PhSOD), and that 
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of its complex with sodium azide. The structures were compared with those of the corresponding 
homologues having a high sequence identity with PhSOD, such as the mesophilic SOD from 
Escherichia coli (EcSOD) or Pseudomonas ovalis, and the psychrophilic SOD from Aliivibrio 
salmonicida (AsSOD). These enzymes shared a large structural similarity, such as a conserved tertiary 
structure and arrangement of the two monomers, an almost identical total number of inter- and 
intramolecular hydrogen bonds and salt bridges. However, the two cold-adapted SODs showed an 
increased flexibility of the active site residues with respect to their mesophilic homologues. Structural 
information was combined with a characterization of the chemical and thermal stability performed by 
CD and fluorescence measurements. Despite of its psychrophilic origin, the denaturation temperature 
of PhSOD was comparable with that of the mesophilic EcSOD, whereas AsSOD showed a lower 
denaturation temperature. On the contrary, the values of the denaturant concentration at the transition 
midpoint were in line with the psychrophilic/ mesophilic origin of the proteins.  
These data provide additional support to the hypothesis that cold-adapted enzymes achieve efficient 
catalysis at low temperature, by increasing the flexibility of their active site; moreover, our results 
underline how fine structural modifications can alter enzyme flexibility and/or stability without 
compromising the overall structure of typical rigid enzymes, such as SODs.  
 
 
 E. Pizzo, A. Merlino, M. Turano, I. Russo Krauss, F. Coscia, A. Zanfardino, M. Varcamonti, 
A. Furia, C. Giancola, L. Mazzarella, F. Sica, G. D'Alessio,  
A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish  
Biochem J.  (2010) DOI: 10.1042/BJ20100892 
Abstract 
Only recently extracellular RNases of the RNase A superfamily, with the characteristic CKxxNTF 
sequence signature, have been identified in fish. This has led to the recognition that these RNases are 
present in the whole vertebrate sub-phylum. In fact, they comprise the only enzyme family unique to 
vertebrates. Four RNases from zebrafish (Danio rerio) have been previously reported, with a very low 
RNase activity, some endowed, like human angiogenin, with powerful angiogenic and bactericidal 
activities. Here we report the three-dimensional structure, the thermodynamic behaviour, and the 
biological properties of a novel zebrafish RNase, ZF-RNase-5. The investigation of its structural and 
functional properties, extended to all other sub-family members. 
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 F. Troise, M. Monti, A. Merlino, F. Cozzolino, C. Fedele, I. Russo Krauss, F. Sica, P. Pucci, G. 
D’Alessio, C. De Lorenzo 
A novel ErbB2 epitope targeted by human antitumor immunoagents Submitted 
Abstract 
Two novel human antitumor immunoconjugates, engineered by fusion of a human anti-ErbB2 scFv, 
termed Erbicin, with either a human RNase or the Fc region of a human IgG1, are selectively cytotoxic 
for ErbB2-positive cancer cells in vitro and in vivo and do not show the most negative properties of 
Herceptin, the only humanized anti-ErbB2 mAb used in the therapy of breast carcinoma: cardiotoxicity 
and inability to act on resistant tumors.  
These differences are likely due to the different ErbB2 epitopes recognized by EDIA and Herceptin as 
it was reported that they induce different signaling mechanisms which control tumor and cardiac cell 
viability.  
Thus, to accurately identify the novel epitope recognized by EDIA, which could also become a 
potential therapeutic target to mitigate anti-ErbB2-associated toxicity and eventually overcome 
resistance, three independent methodologies were used which gave coherent results, here reported: 
EDIA bind to a different ErbB2 epitope, if compared to Herceptin and the other human/humanized 
anti-ErbB2 antibodies reported so far, and this epitope is located in the region 122-195 of extracellular 
domain I of ErbB2. 
 
 
 I. Russo Krauss, A. Merlino, C. Giancola, A. Randazzo, L. Mazzarella, F. Sica 
A revealed ambiguity: the crystal structure of α-thrombin in complex with modified thrombin binding 
aptamer In preparation 
 
 A. Merlino, I. Russo Krauss, I. Castellano, E. De Vendittis, A. Vergara, F. Sica, 
Structural and denaturation studies of two mutants of a cold adapted superoxide dismutase point to the 
importance of electrostatic interactions in protein stability In preparation 
 
 A. Merlino, I. Russo Krauss, I. Castellano, E. De Vendittis, B. Rossi, A. Vergara, F. Sica 
Spectroscopic analysis of temperature and guanidinium chloride-induced unfolding of the superoxide 
dismutase from the denthal pathogenic microorganism Streptococcus mutans supports a three state 
mechanism In preparation 
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Structures published in Protein Data Bank 
PDB code  
3FKZ X-ray structure of the non covalent swapped form of the  
S16G/T17N/A19P/A20S/K31C/S32C mutant of bovine pancreatic ribonuclease 
A. Merlino, I. Russo Krauss, M. Perillo, C. Ercole, D. Picone, A. Vergara, F. Sica. 
(24-03-2009) DOI: 10.2210/pdb3fkz/pdb 
3FL0 X-ray structure of the non covalent swapped form of the Q28L/K31C/S32C 
mutant of bovine pancreatic ribonuclease in complex with 2'-DEOXYCYTIDINE- 
-2'-DEOXYGUANOSINE-3',5'-MONOPHOSPHATE 
A. Merlino, I. Russo Krauss, M. Perillo, C. Ercole, D. Picone, A. Vergara, F. Sica.  
(24-03-2009) DOI: 10.2210/pdb3fl0/pdb 
3FL1  X-ray structure of the non covalent swapped form of the A19P/Q28L/K31C/S32C 
mutant of bovine pancreatic ribonuclease in complex with 2'-DEOXYCYTIDINE- 
-2'-DEOXYGUANOSINE-3',5'-MONOPHOSPHATE 
A. Merlino, I. Russo Krauss, M. Perillo, C. Ercole, D. Picone, A. Vergara, F. Sica.  
(24-03-2009) DOI: 10.2210/pdb3fl1/pdb 
3FL3 X-ray structure of the ligand free non covalent swapped form of the 
A19P/Q28L/K31C/S32C mutant of bovine pancreatic ribonuclease 
A. Merlino, I. Russo Krauss, M. Perillo, C. Ercole, D. Picone, A. Vergara, F. Sica.  
(24-03-2009) DOI: 10.2210/pdb3fl3/pdb 
3LIO  The X-ray structure of iron superoxide dismutase from Pseudoalteromonas   
  haloplanktis (crystal form I) 
A. Merlino, I. Russo Krauss,  B. Rossi, M. Conte, A. Vergara, F. Sica  
  (08-09-2010) DOI: 10.2210/pdb3lio/pdb 
3LJF  The X-ray structure of iron superoxide dismutase from Pseudoalteromonas   
  haloplanktis (crystal form II) 
  A. Merlino, I. Russo Krauss, B. Rossi, M. Conte, A. Vergara, F. Sica 
  (08-09-2010) DOI: 10.2210/pdb3ljf/pdb 
3LJ9  The X-ray structure of iron superoxide dismutase from Pseudoalteromonas   
  haloplanktis in complex with sodium azide  
A. Merlino, I. Russo Krauss,  B. Rossi, M. Conte, A. Vergara, F. Sica 
  (08-09-2010) DOI: 10.2210/pdb3lj9/pdb 
3LJE  The X-ray structure of zebrafish RNase5 
  I. Russo Krauss, A. Merlino, F. Coscia, L. Mazzarella, F. Sica 
  (24-11-2010) DOI: 10.2210/pdb3lje/pdb 
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3LJD  The X-ray structure of zebrafish RNase1 from a new crystal form at pH 4.5 
I. Russo Krauss,  A. Merlino, L. Mazzarella, F. Sica  
  DOI: 10.2210/pdb3ljd/pdb 
3LN8  The X-ray structure of zebrafish RNase1 from a new crystal form at pH 7.3 
I. Russo Krauss,  A. Merlino, L. Mazzarella, F. Sica  
  DOI: 10.2210/pdb3ln8/pdb 
 
 
